

Cigna Medical Coverage Policies – Radiology Pediatric Head Imaging Guidelines

Effective August 15, 2023



Instructions for use

The following coverage policy applies to health benefit plans administered by Cigna. Coverage policies are intended to provide guidance in interpreting certain standard Cigna benefit plans and are used by medical directors and other health care professionals in making medical necessity and other coverage determinations. Please note the terms of a customer's particular benefit plan document may differ significantly from the standard benefit plans upon which these coverage policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a coverage policy.

In the event of a conflict, a customer's benefit plan document always supersedes the information in the coverage policy. In the absence of federal or state coverage mandates, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of:

1. The terms of the applicable benefit plan document in effect on the date of service
2. Any applicable laws and regulations
3. Any relevant collateral source materials including coverage policies
4. The specific facts of the particular situation

Coverage policies relate exclusively to the administration of health benefit plans. Coverage policies are not recommendations for treatment and should never be used as treatment guidelines.

This evidence-based medical coverage policy has been developed by eviCore, Inc. Some information in this coverage policy may not apply to all benefit plans administered by Cigna.

These guidelines include procedures eviCore does not review for Cigna. Please refer to the [Cigna CPT code list](#) for the current list of high-tech imaging procedures that eviCore reviews for Cigna.

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright 2023 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

Pediatric Head Imaging	
Procedure Codes Associated with Head Imaging	3
General Guidelines (PEDHD-1)	5
Specialized Imaging Techniques (PEDHD-2)	13
Pediatric Headache (PEDHD-3)	16
Pediatric Head and Face Trauma (PEDHD-4)	19
Sinus and Facial Imaging (PEDHD-5)	22
Epilepsy and Other Seizure Disorders (PEDHD-6)	26
Macrocephaly, Microcephaly, and Hydrocephalus (PEDHD-7)	31
Craniosynostosis/Cleft Palate (PEDHD-8)	36
Chiari and Skull Base Malformations (PEDHD-9)	39
Intracranial Aneurysms and AVM (PEDHD-10)	43
Syncope (PEDHD-11)	48
Pediatric Stroke (PEDHD-12)	49
Benign Brain Lesions (PEDHD-13)	55
Pediatric Demyelinating Diseases (PEDHD-14)	57
Pituitary Dysfunction (PEDHD-15)	62
Pediatric Ear Disorders (PEDHD-16)	68
Autism Spectrum Disorders (PEDHD-17)	73
Behavioral and Psychiatric Disorders (PEDHD-18)	74
Developmental Disorders (PEDHD-19)	75
Ataxia (PEDHD-20)	78
Epistaxis (PEDHD-21)	79
Pseudotumor Cerebri (PEDHD-22)	80
Cranial Neuropathies (PEDHD-23)	81
Pediatric Sleep Disorders (PEDHD-24)	82
Temporomandibular Joint (TMJ)/Dental/Maxillofacial Imaging in Children (PEDHD-25)	83
Movement Disorders including Tourette's Syndrome (PEDHD-26)	85
Tuberous Sclerosis (PEDHD-27)	88
Von Hippel Lindau Syndrome (VHL) (PEDHD-28)	89
CNS Infection (PEDHD-29)	90
Scalp and Skull Lesions (PEDHD-30)	92
Eye Disorders (PEDHD-31)	93

Procedure Codes Associated with Head Imaging	
MRI	CPT®
MRI Brain without contrast	70551
MRI Brain with contrast (rarely used)	70552
MRI Brain without and with contrast	70553
MRI Orbit, Face, Neck without contrast	70540
MRI Orbit, Face, Neck with contrast (rarely used)	70542
MRI Orbit, Face, Neck without and with contrast	70543
MRI Temporomandibular Joint (TMJ)	70336
Functional MRI Brain not requiring physician or psychologist	70554
Functional MRI Brain requiring physician or psychologist	70555
MR Spectroscopy	76390
Unlisted MRI procedure (for radiation planning or surgical software)	76498
MRA	CPT®
MRA Head without contrast	70544
MRA Head with contrast	70545
MRA Head without and with contrast	70546
MRA Neck without contrast	70547
MRA Neck with contrast	70548
MRA Neck without and with contrast	70549
CT	CPT®
CT Head without contrast	70450
CT Head with contrast	70460
CT Head without and with contrast	70470
CT Orbits without contrast (includes temporal bone and mastoid)	70480
CT Orbits with contrast (includes temporal bone and mastoid)	70481
CT Orbits without and with contrast (includes temporal bone and mastoid)	70482
CT Maxillofacial without contrast (includes sinuses, jaw, and mandible)	70486
CT Maxillofacial with contrast (includes sinuses, jaw, and mandible)	70487
CT Maxillofacial without and with contrast (includes sinuses, jaw, and mandible)	70488
CT Neck without contrast (includes jaw, and mandible)	70490
CT Neck with contrast (includes jaw, and mandible)	70491
CT Neck without and with contrast (includes jaw, and mandible)	70492
CT Guidance for Stereotactic Localization (used for sinus surgery planning)	77011
CT Guidance for Placement of Radiation Therapy Fields	77014
Unlisted CT procedure (for radiation planning or surgical software)	76497
CTA	CPT®
CTA Head	70496
CTA Neck	70498

Ultrasound	CPT®
Echoencephalography (Head or Cranial Ultrasound)	76506
Ophthalmic ultrasound, diagnostic; B-scan & quantitative A-scan performed same encounter	76510
Ophthalmic ultrasound, diagnostic; quantitative A-scan only	76511
Ophthalmic ultrasound, diagnostic; B-scan	76512
Ophthalmic ultrasound, diagnostic; anterior segment ultrasound, immersion (water bath) B-scan	76513
Ophthalmic ultrasound, diagnostic; corneal pachymetry, unilateral or bilateral	76514
Ophthalmic biometry by ultrasound, A-scan	76516
Ophthalmic biometry by ultrasound, A-scan, with lens power calculation	76519
Ophthalmic ultrasonic foreign body localization	76529
Soft tissues of head and neck Ultrasound (thyroid, parathyroid, parotid, etc.)	76536
Transcranial Doppler study of the intracranial arteries; complete study	93886
Transcranial Doppler study of the intracranial arteries; limited study	93888
Transcranial Doppler study of the intracranial arteries; vasoreactive study	93890
Transcranial Doppler study of the intracranial arteries; emboli detection without intravenous microbubble injection	93892
Transcranial Doppler study of the intracranial arteries; emboli detection with intravenous microbubble injection	93893
Duplex scan of extracranial arteries; complete bilateral study	93880
Duplex scan of extracranial arteries; unilateral or limited study	93882
Non-invasive physiologic studies of extracranial arteries, complete bilateral study	93875

General Guidelines (PEDHD-1)	
General Guidelines (PEDHD-1.0)	6
Pediatric Head Imaging Age Considerations (PEDHD-1.1)	6
Pediatric Head Imaging Appropriate Clinical Evaluation (PEDHD-1.2)	7
Pediatric Head Imaging Modality General Considerations (PEDHD-1.3)	7
General Guidelines-Other Imaging Situations (PEDHD-1.4)	10

General Guidelines (PEDHD-1.0)

- A pertinent clinical evaluation including a detailed history, physical examination with a thorough neurologic examination since the onset or change in signs and/or symptoms²⁹, appropriate laboratory studies and basic imaging such as plain radiography or ultrasound should be performed prior to considering advanced imaging (CT, MR, Nuclear Medicine), unless the individual is undergoing guideline-supported scheduled imaging evaluation. A meaningful technological contact (telehealth visit, telephone call, electronic mail or messaging) since the onset or change in signs and/or symptoms²⁹, can serve as a pertinent clinical evaluation.
 - ◆ A detailed neurological exam is required prior to advanced imaging except in the following scenarios:
 - Individual is undergoing a guideline-supported scheduled follow-up imaging evaluation
 - Tinnitus, TMJ, Sinus or mastoid disease, ear pain, hearing loss, eye disease, papilledema³⁰, dental requests and epistaxis. (A relevant physical exam is still required.)
 - The request is from a neurologist, neurosurgeon, endocrinologist, otolaryngologist, or ophthalmologist who has evaluated the individual since onset of symptoms.
- Unless otherwise stated in a specific guideline section, the use of advanced imaging to screen asymptomatic individuals for disorders involving the head is not supported. Advanced imaging of the head is only indicated in individuals who have documented active clinical signs or symptoms of disease involving the head.
- Unless otherwise stated in a specific guideline section, repeat imaging studies of the head are not necessary unless there is evidence for progression of disease, new onset of disease, and/or documentation of how repeat imaging will affect individual management or treatment decisions.

Pediatric Head Imaging Age Considerations (PEDHD-1.1)

- Many conditions affecting the head in the pediatric population are different diagnoses than those occurring in the adult population. For those diseases which occur in both pediatric and adult populations, minor differences may exist in management due to individual age, comorbidities, and differences in disease natural history between children and adults.
- Individuals who are 18 years old or younger³¹ and any conditions not specifically discussed in the General Head Imaging Guidelines should be imaged according to the Pediatric Head Imaging Guidelines. Any conditions not specifically discussed in the Pediatric Head Imaging Guidelines should be imaged according to the General Head Imaging Guidelines. Individuals who are >18 years old should be imaged according to the General Head Imaging Guidelines, except where directed otherwise by a specific guideline section.

Pediatric Head Imaging Appropriate Clinical Evaluation (PEDHD-1.2)

Requests for Studies with Overlapping Fields

- There are many CPT® codes for imaging the head that have significantly overlapping fields. In the majority of cases where multiple head CPT® codes are requested, only one CPT® code is appropriate unless there is clear documentation of a need for the additional codes to cover all necessary body areas.
- See **General Guidelines - Anatomic Issues (HD-1.1)** in the Head Imaging Guidelines for the correct coding of these studies.

Pediatric Head Imaging Modality General Considerations (PEDHD-1.3)

- MRI
 - ◆ MRI is the preferred modality for imaging the pediatric head unless otherwise stated in a specific guideline section.
 - ◆ Due to the length of time required for MRI acquisition and the need to minimize individual movement, anesthesia is usually required for almost all infants (except neonates) and young children (age <7 years) as well as older children with delays in development or maturity. This anesthesia may be administered via oral or intravenous routes. In this individual population, MRI sessions should be planned with a goal of minimizing anesthesia exposure by adhering to the following considerations:
 - MRI procedures can be performed without and/or with contrast use as supported by these condition based guidelines. If intravenous access will already be present for anesthesia administration and there is no contraindication for using contrast, imaging without and with contrast may be appropriate if requested. By doing so, the requesting provider may avoid repetitive anesthesia administration to perform an MRI with contrast if the initial study without contrast is inconclusive.
 - ◆ Recent evidence based literature demonstrates the potential for gadolinium deposition in various organs including the brain, after the use of MRI contrast.
 - The U.S. Food and Drug Administration (FDA) has noted that there is currently no evidence to suggest that gadolinium retention in the brain is harmful and restricting gadolinium-based contrast agents (GBCAs) use is not warranted at this time. It has been recommended that GBCA use should be limited to circumstances in which additional information provided by the contrast agent is necessary and the necessity of repetitive MRIs with GBCAs should be assessed.
 - ◆ If multiple body areas are supported by eviCore guidelines for the clinical condition being evaluated, MRI/MRA of all necessary body areas should be obtained concurrently in the same anesthesia session.

➤ CT

- ◆ CT is generally inferior to MRI for imaging the pediatric head, but has specific indications in which it is the preferred modality listed in specific sections of these guidelines.
 - CT should not be used to replace MRI in an attempt to avoid sedation unless listed as a recommended study in a specific guideline section.
- ◆ CT Head without contrast (CPT® 70450) may be indicated for:
 - Mass effect
 - Blood/blood products
 - Urgent/emergent settings due to availability and speed of CT
 - Trauma
 - Recent hemorrhage, whether traumatic or spontaneous
 - Bony structures of the head evaluations including dystrophic calcifications
 - Hydrocephalus evaluation and follow-up
 - Some centers use limited non-contrast “fast or rapid MRI” (CPT® 70551) to minimize radiation exposure in children - these requests are appropriate.
 - Prior to lumbar puncture in individuals with cranial complaints
 - Scenarios in which MRI is contraindicated (i.e. pacemakers, ICDs, cochlear implants, aneurysm clips, orbital metallic fragments, etc.)

➤ CT and MR Angiography (CTA and MRA) Head and Neck

- ◆ MRA Head may be performed without contrast (CPT® 70544), with contrast (CPT® 70545), or without and with contrast (CPT® 70546).
- ◆ CTA Head is performed without and with contrast (CPT® 70496).
- ◆ MRA Neck may be done either without contrast (CPT® 70547), with contrast (CPT® 70548), or without and with contrast (CPT® 70549), depending on facility preference and protocols and type of scanner.
- ◆ CTA Neck is done with and without contrast (CPT® 70496)

➤ Indications for CTA and MRA Head and Neck vessels include, but are not limited to the following:

- ◆ MRA is the preferred study in children unless contraindicated:
 - Pulsatile tinnitus
 - Hemifacial spasm if consideration for surgical decompression
 - Evaluation of stroke or TIA (See **Pediatric Stroke Initial Imaging (PEDHD-12.2)**, **Pediatric Stroke Subsequent Imaging (PEDHD-12.3)**, **Moyamoya Disease (PEDHD-12.4)**, **Sickle Cell Disease (PEDHD-12.5)** and **CNS Vasculitis and Stroke (PEDHD-12.6)** including collateral assessment)
 - Follow up of known cerebral artery stenosis
 - Trigeminal neuralgia that has failed medical therapy
 - Cerebral sinus thrombosis suspected with increased intracranial pressure (refractory headaches, papilledema, diagnosis of pseudotumor cerebri)
 - Aneurysm suspected with acute “thunderclap” headache syndrome and appropriate screening or evaluation of known subarachnoid hemorrhage and pseudoaneurysms (may be appropriate to limit CTA to include only the head to avoid unnecessary radiation to the individual) (See **Pediatric Intracranial Aneurysms (PEDHD-10.1)**)

- Noninflammatory vasculopathy, including radiation vasculopathy (See **Long Term Pediatric Cancer Survivors (PEDONC-19)** in the Pediatric Oncology Imaging Guidelines)
- Traumatic vascular injuries
- Vascular malformations, vascular anatomic variants and fistulas (See **Pediatric Intracranial Arteriovenous Malformations (AVM) (PEDHD-10.2)**)
- Arterial, including carotid dissections
- Tumors of vascular origin or involving vascular structures
- Surgical and radiation therapy localization, planning and neuronavigation
- Evaluation for vascular intervention and follow-up including postsurgical/posttreatment vascular complications
- Intra-cranial pre-operative planning if there is concern of possible vascular involvement or risk for vascular complication from procedure
- Vasculitis and collagen vascular disease (See **CNS Vasculitis and Stroke (PEDHD-12.6)**)
- Sickle cell disease (See **Sickle Cell Disease (PEDHD-12.5)**)
- Moyamoya disease (See **Moyamoya Disease (PEDHD-12.4)**)
- ◆ MRA Head without, with, or without and with contrast or CTA Head for follow up of aneurysm clipping or coiling procedures (See **Intracranial Aneurysms (HD-12.1)** in the Head Imaging Guidelines)
- ◆ CT and MR Venography (CTV and MRV) are reported with the same codes as the CTA/MRA counterpart (there is no specific code for CT/MR venography):
 - If arterial and venous CT or MR studies are both performed in the same session, only one CPT® code should be used to report both procedures
- ◆ MRA without and with contrast with venous sinus thrombosis to differentiate total from subtotal occlusion
- NOTE: Evaluation of posterior circulation disease requires both neck and head MRA/CTA to visualize the entire vertebral-basilar system
- Ultrasound
 - ◆ Cranial ultrasound (CPT® 76506) is a non-invasive means of evaluating for intracranial abnormalities in infants with an open anterior fontanelle.
 - ◆ Transcranial Doppler ultrasonography has some utility in select populations of older children with known or suspected intracranial vascular disease.
- 3D Rendering
 - ◆ CPT® 76377 (3D rendering requiring image post-processing on an independent workstation) can be considered in the following clinical scenarios:
 - Bony conditions:
 - Evaluation of congenital skull abnormalities in newborns, infants, and toddler (usually for preoperative planning)
 - Complex joint fractures or pelvis fractures
 - Spine fractures (usually for preoperative planning)
 - Complex facial fractures
 - Preoperative planning for other complex surgical cases
 - Cerebral angiography
 - ◆ 3D Rendering (CPT® 76377) may be used for surgical planning and surgical follow up after craniotomy when ordered by surgical specialist

- ◆ 3D Rendering indications in pediatric head imaging are identical to those in the general imaging guidelines. See **3D Rendering (Preface-4.1)** in the Preface Imaging Guidelines
- The guidelines listed in this section for certain specific indications are not intended to be all-inclusive; clinical judgment remains paramount and variance from these guidelines may be appropriate and warranted for specific clinical situations.

Background and Supporting Information

- “The U.S. Food and Drug Administration (FDA) is warning that repeated or lengthy use of general anesthetic and sedation drugs during surgeries or procedures in children younger than 3 years or in pregnant women during their third trimester may affect the development of children’s brains. ... Published studies in pregnant animals and young animals have shown the use of general anesthetic and sedation drugs for more than 3 hours caused widespread loss of nerve cells in the brain. ... All the studies in children had limitations, and it is unclear whether any negative effects seen in children’s learning or behavior were due to the drugs or to other factors, such as the underlying medical condition that led to the need for the surgery or procedure.”²⁸

General Guidelines-Other Imaging Situations (PEDHD-1.4)

- MRI Brain without contrast (CPT® 70551) or MRI Brain with and without contrast (CPT® 70553) can be performed for nausea and vomiting, persistent, unexplained and a negative GI evaluation
- MRI Brain without contrast (CPT® 70551) or MRI Brain without and with contrast (CPT® 70553) is approvable in the presence of neurological signs and/or symptoms, including headache, after COVID-19 infection
- Screening for metallic fragments before MRI should be done initially with Plain x-ray.
 - ◆ The use of CT Orbital to rule out orbital metallic fragments prior to MRI is rarely necessary
 - ◆ Plain x-rays are generally sufficient; x-ray detects fragments of 0.12 mm or more, and CT detects those of 0.07 mm or more
 - ◆ Plain x-ray is generally sufficient to screen for aneurysm clips
- CPT® 76377 (3D rendering requiring image post-processing on an independent workstation) can be considered when performed in conjunction with conventional angiography (i.e.: conventional 4 vessel cerebral angiography).
- MRI Brain with and without contrast (CPT® 70553) is appropriate in consideration of neurosarcoidosis

- CT or MRI Perfusion (See **CT or MRI Perfusion (HD-24.5)** in the Head Imaging Guidelines)
 - ◆ Performed as part of a CT Head or MRI Brain examination in the evaluation of individuals with very new strokes or brain tumors.
 - ◆ Category III 0042T - “cerebral perfusion analysis using CT”. The study is generally limited to evaluation of acute stroke (<24 hours), to help identify individuals with stroke-like symptoms most likely to benefit from thrombolysis or thrombectomy, to assist in planning and evaluating the effectiveness of therapy for cervical or intracranial arterial occlusive disease and/or chronic cerebral ischemia, identifying cerebral hyperperfusion syndrome following revascularization and following aneurysmal subarachnoid hemorrhage. Other indications are usually regarded as investigational and experimental. See **Moyamoya Disease (PEDHD-12.4)**
 - ◆ There is no specific CPT® code for MRI Perfusion. Perfusion weighted images are obtained with contrast and are not coded separately from a contrasted MRI Brain examination. If MRI Brain without and with contrast is approved, no additional CPT® codes are necessary or appropriate to perform MRI perfusion.

References

1. Siegel MJ. Brain. In: Pediatric sonography. 5th ed. Philadelphia, Wolters Kluwer. 2018. 40-111.
2. Prabhu SP, and Young-Poussaint Ty. Pediatric central nervous system emergencies. Neuroimag Clin N Am. 2010 Nov; 20 (4): 663-683.
3. Patra KP, Lancaster JD, Hogg J, et al. Pediatric MRI of the Brain: a primer. Pediatr Rev. 2014 Mar; 35 (3):106-113.
4. Ing C, DiMaggio C, Whitehouse A, et al. Long-term differences in language and cognitive function after childhood exposure to anesthesia. Pediatrics. 2012 Sep; 130 (3): e476-e485.
5. Monteleone M, Khandji A, Cappell J, et al. Anesthesia in children: perspectives from nonsurgical pediatric specialists. J Neurosurg Anesthesiol. 2014; 26 (4): 396-398.
6. DiMaggio C, Sun LS, and Li G. Early childhood exposure to anesthesia and risk of developmental and behavioral disorders in a sibling birth cohort. Anesth Analg. 2011; 113: 1143-1151.
7. Nakagawa TA, Ashwal S, Mathur M, Mysore M. the Committee for Determination of. Guidelines for the determination of brain death in infants and children: An Update of the 1987 Task Force Recommendations- Executive Summary. Annals of Neurology. 2012;71(4):573-585. doi:10.1002/ana.23552.
8. Donohoe KJ, Agrawal G, Frey KA, et al. SNMPPractice Guideline for Brain Death Scintigraphy 2.0 *Journal of Nuclear Medicine Technology*. 2012;40(3):198-203. doi:10.2967/jnmt.112.105130.
9. MacDonald A, and Burrell S. Infrequently performed studies in nuclear medicine: Part 2. J Nucl Med Technol. 2009 Mar; 37: 1-13.
10. Fraum TJ, Ludwig DR, Bashir MR, et al. Gadolinium-based contrast agents: a comprehensive risk assessment. J Magn Reson Imaging. 2017; 46:338–353.
11. FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings. 5-16-2018 Update. May 22, 2017. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-gadolinium-based-contrast-agents-gbcas-are-retained-body>.
12. ACR - AIUM -SPR -SRU Practice parameter for the performance of neurosonography in neonates and infants. American College of Radiology. Revised March, 2020 <https://onlinelibrary.wiley.com/doi/10.1002/jum.15264>.
13. Sodhi K, Gupta P, Saxena A, Khandelwal N, Singhi P. Neonatal cranial sonography: A concise review for clinicians. Journal of Pediatric Neurosciences. 2016;11(1):7. doi:10.4103/1817-1745.181261.
14. ACR- ASNR-SPR Practice Parameter for the Performance of Computed Tomography (CT) of the Extracranial Head and Neck Revised 2021. (Resolution 5). <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/CT-Head-Neck>.
15. Stern BJ, Royal W, Gelfand JM, et al. Definition and Consensus Diagnostic Criteria for Neurosarcoidosis. JAMA Neurology. 2018;75(12):1546. doi:10.1001/jamaneurol.2018.2295.
16. Shosha E, Dubey D, Palace J, et al. Area postrema syndrome. Neurology. 2018;91(17). doi:10.1212/wnl.00000000000006392.
17. Hornby PJ. Central neurocircuitry associated with emesis. The American Journal of Medicine. 2001;111(8):106-112. doi:10.1016/s0002-9343(01)00849-x.

18. ACR-ASNR- SPR Practice Parameters for the performance of Computed Tomography (CT) perfusion in neuroradiologic imaging. Revised 2017. (Resolution 18). <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/CT-Perfusion.pdf>.
19. Blumfield E, Swenson DW, Iyer RS, Stanescu AL. Gadolinium-based contrast agents — review of recent literature on magnetic resonance imaging signal intensity changes and tissue deposits, with emphasis on pediatric patients. *Pediatric Radiology*. 2019;49(4):448-457. doi:10.1007/s00247-018-4304-8.
20. ACR ASNR SPR Practice Parameter for the Performance and Interpretation of Cervicocerebral Computed Tomography Angiography (CTA) Revised 2020. <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/CervicoCerebralCTA.pdf?la=en>
21. ACR ASNR SPR Practice Parameter for the Performance and Interpretation of Magnetic Resonance Imaging (MRI) of the Brain. Revised 2019. <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/MR-Brain.pdf>
22. ACR-ASNR-SPR Practice Parameter for the Performance of Cervicocerebral Magnetic Resonance Angiography (MRA) Revised 2020 <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/cervicocerebralmra.pdf?la=en>.
23. Drug Safety Communication: FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women. 12/14/2016. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-review-results-new-warnings-about-using-general-anesthetics-and?source=govdelivery&utm_medium=email&utm_source=govdelivery
24. Drug Safety Communication: FDA approves label changes for use of general anesthetic and sedation drugs in young children. 4-27-2017 Update. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-approves-label-changes-use-general-anesthetic-and-sedation-drugs>
25. Response to the FDA Med Watch December 16, 2016. American Academy of Pediatrics. https://www.aap.org/en-us/_layouts/15/WopiFrame.aspx?sourcedoc=/en-us/Documents/Response_FDA_12-16_Statement.docx&action=default
26. Artunduaga M, Liu CA, Morin CE, et al. Safety challenges related to the use of sedation and general anesthesia in pediatric patients undergoing magnetic resonance imaging examinations. *Pediatr Radiol*. 2021;51(5):724-735. doi:10.1007/s00247-021-05044-5
27. ACR–AIUM–SPR–SRU PRACTICE PARAMETER FOR THE PERFORMANCE OF NEUROSONOGRAPHY IN NEONATES AND INFANTS <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/Neurosonog.pdf>
28. ACR–ASNR–SPR PRACTICE PARAMETER FOR THE PERFORMANCE OF COMPUTED TOMOGRAPHY (CT) OF THE HEAD <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/CT-Head.pdf>.
29. History and Physicals - Understanding the Requirements at <https://www.jointcommission.org/standards/standard-faqs/critical-access-hospital/medical-staff-ms/000002272/?p=1>
30. Aylward SC, Reem RE. Pediatric Intracranial Hypertension. *Pediatr Neurol*. 2017 Jan;66:32-43. doi: 10.1016/j.pediatrneurol.2016.08.010.
31. Implementation Guide: Medicaid State Plan Eligibility Eligibility Groups Mandatory Coverage Infants and Children under Age 19 Guidance Portal. <https://www.hhs.gov/guidance/document/implementation-guide-medicaid-state-plan-eligibility-eligibility-groups-aeu-mandatory-2>.

Specialized Imaging Techniques (PEDHD-2)	
Magnetic Resonance Spectroscopy (MRS, CPT® 76390) (PEDHD-2.1)	14
Functional Magnetic Resonance Imaging (fMRI, CPT® 70554 and CPT® 70555) (PEDHD-2.2)	14
PET Brain Imaging (CPT® 78608) (PEDHD-2.3)	14

Magnetic Resonance Spectroscopy (MRS, CPT® 76390) (PEDHD-2.1)

- Magnetic Resonance Spectroscopy involves the analysis of the levels of certain chemicals in pre-selected voxels (small regions) on an MRI scan done at the same time.
- Uses in pediatric neuro-oncology: See **Pediatric CNS Tumors (PEDONC-4)** in the Pediatric Oncology Imaging Guidelines.
- MRS is indicated in individuals with neonatal hypoxic ischemic encephalopathy to help estimate the age of the injury.
- Uses in Metabolic Disorders:
 - ◆ See **Neurometabolic and Neurogenetic Disorders (PEDHD-19.4)**
- MRS is considered investigational for all other pediatric indications at this time.

Functional Magnetic Resonance Imaging (fMRI, CPT® 70554 and CPT® 70555) (PEDHD-2.2)

- MRI is indicated to define eloquent areas of the brain as part of preoperative planning for epilepsy surgery or removal of a mass lesion.
 - ◆ The documentation should be clear that brain surgery is planned.
 - ◆ Can be performed concurrently with MRI Brain (CPT® 70551 or CPT® 70553) and/or PET Brain Metabolic (CPT® 78608 or CPT® 78609).
- fMRI is considered investigational for all other pediatric indications at this time.

PET Brain Imaging (CPT® 78608) (PEDHD-2.3)

- Uses in pediatric neuro-oncology: See **Pediatric CNS Tumors (PEDONC-4)** in the Pediatric Oncology Imaging Guidelines.
- Metabolic (FDG) PET Brain is indicated to define active areas of the brain as part of preoperative planning for epilepsy surgery. The documentation should be clear that brain surgery is planned.
 - ◆ Can be appropriate concurrently with MRI Brain (CPT® 70551 or CPT® 70553) and/or fMRI (CPT® 70554 or CPT® 70555).
- Metabolic (FDG) PET Brain/MRI is generally not supported for neurologic conditions due to lack of standardization in imaging technique and interpretation. However, it can be appropriate in certain pediatric individuals when ALL of the following criteria are met:
 - ◆ The individual meets guideline criteria for Metabolic (FDG) PET/CT Brain AND
 - ◆ Metabolic (FDG) PET/CT Brain is not available at the treating institution AND
 - ◆ The provider requests Metabolic (FDG) PET Brain/MRI in lieu of Metabolic (FDG) PET/CT Brain
- Metabolic (FDG) PET Brain/MRI, when the above criteria are met, are reported using the code combination of Metabolic (FDG) PET Brain (CPT® 78608) and MRI Brain (CPT® 70551 or CPT® 70553). All other methods of reporting Metabolic (FDG) PET Brain/MRI are inappropriate
 - ◆ When clinically appropriate, diagnostic MRI codes can be appropriate at the same time as the Metabolic (FDG) PET Brain/MRI code combination
- Metabolic (FDG) PET Brain is considered investigational for all other pediatric indications at this time.

References

1. Hertz-Pannier L, Noulhaine M, Rodrigo S, et al. Pretherapeutic functional magnetic resonance imaging in children. *Neuroimag Clin N Am*. 2014 Nov; 24 (4): 639-653.
2. Patra KP, Lancaster JD, Hogg J, et al. Pediatric MRI of the brain: a primer. *Pediatr Rev*. 2014 Mar; 35 (3):106-111.
3. Schneider JF. MR Spectroscopy in children: protocols and pitfalls in non-tumorous brain pathology. *Pediatr Radiol*. 2016 Jun; 46 (7): 963-982.
4. Expert Panel on Pediatric Imaging, Trofimova A, Milla SS, et al. ACR Appropriateness Criteria® Seizures-Child. *J Am Coll Radiol*. 2021;18(5S):S199-S211. doi:10.1016/j.jacr.2021.02.020
5. Ramey WL, Martirosyan NL, Lieu CM, et al. Current management and surgical outcomes of medically intractable epilepsy. *Clin Neurol Neurosurg*. 2013 Dec; 115 (12): 2411-2418.
6. Ghei SK, Zan E, Nathan JE, et al. MR Imaging of Hypoxic-Ischemic Injury in Term Neonates: Pearls and Pitfalls. *RadioGraphics*. 2014;34(4):1047-1061. doi:10.1148/rq.344130080.
7. Schwartz ES, Barkovich AJ. Brain and spine injuries in infancy and childhood. In: Barkovich AJ, Raybaud C, eds. *Pediatric Neuroimaging*, 6th ed. Philadelphia PA. Wolters Kluwer. 2019; 263-404.
8. Boerwinkle VL, Cediel EG, Mirea L, et al. Network-targeted approach and postoperative resting-state functional magnetic resonance imaging are associated with seizure outcome. *Annals of Neurology*. 2019;86(3):344-356. doi:10.1002/ana.25547.
9. Yahyavi-Firouz-Abadi N, Pillai J, Lindquist M, et al. Presurgical Brain Mapping of the Ventral Somatomotor Network in Patients with Brain Tumors Using Resting-State fMRI. *American Journal of Neuroradiology*. 2017;38(5):1006-1012. doi:10.3174/ajnr.a5132.
10. Szaflarski JP, Gloss D, Binder JR, et al. Practice guideline summary: Use of fMRI in the presurgical evaluation of patients with epilepsy. *Neurology*. 2017;88(4):395-402. doi:10.1212/wnl.0000000000003532.

Pediatric Headache (PEDHD-3)

Pediatric Headache (PEDHD-3.1)

- Headache is a very common complaint in school aged children and adolescents. Many of these children have a family history of one of the primary headache disorders, such as migraine or tension headache.
- A pertinent clinical evaluation including a detailed history, physical examination with a thorough neurologic examination, since the onset or change in signs and/or symptoms, and appropriate laboratory studies should be performed prior to considering advanced imaging.
- Advanced imaging is not indicated for pediatric individuals with headache in the absence of red flag symptoms.
- Sensitivity and specificity of MRI are greater than that of CT for intracranial lesions.
- MRI Brain without contrast (CPT® 70551) or without and with contrast (CPT® 70553) is indicated for children with headaches and at least ONE of the following red flags:
 - ◆ Age ≤5 years.
 - ◆ Headaches awakening from sleep or always present in the morning.
 - ◆ Focal findings, and/or symptoms on neurologic examination including diplopia.
 - ◆ Clumsiness (common description of gait or coordination problems in young children).
 - ◆ Headaches associated with morning nausea/vomiting.
 - ◆ New onset of seizure activity with focal features.
 - ◆ Papilledema on physical exam.
 - ◆ Headache precipitated by coughing, sneezing, physical exertion¹², or Valsalva.
 - ◆ Thunderclap headache.
 - ◆ Progressive worsening in headache frequency and severity without period of temporary improvement.
 - ◆ Systemic symptoms such as persistent fever, weight loss, rash, or joint pain.
 - ◆ Immunocompromised individual.
 - ◆ Individual with hypercoagulable state or bleeding disorder.
 - ◆ Known history of cancer of any type.
 - ◆ Known autoimmune or rheumatologic disease.
 - ◆ Known genetic disorder with predisposition to intracranial mass lesions.
 - ◆ History of stable chronic headaches with recent significant change in frequency or severity.
- MRI Brain without contrast (CPT® 70551) or MRI Brain without and with contrast (CPT® 70553) is appropriate in the presence of neurological signs and/or symptoms, including headache, after COVID-19 infection
- If concern for CNS infection – See **CNS Infection (PEDHD-29)**
- CT Head poorly visualizes the posterior fossa in children and is generally insufficient to evaluate pediatric headaches with red flag symptoms. CT is not supported in lieu of MRI solely to avoid sedation.

- CT Head without contrast (CPT® 70450) is indicated for pediatric headache with one or more of the following:
 - ◆ Sudden severe headache including thunderclap headache
 - ◆ Acute setting of suspected intracranial infection prior to lumbar puncture (CT Head with contrast CPT® 70460 if intracranial spread of disease is suspected to detect suppurative fluid collections) (See **General Guidelines-Other Imaging Situations (PEDHD-1.4)**)
 - ◆ To exclude new hemorrhage, significant mass effect, or hydrocephalus in cases including rapid clinical deterioration
 - ◆ Recent head trauma.
 - ◆ Suspected skull or other bony involvement.
 - ◆ If MRI is contraindicated
 - ◆ Ventriculoperitoneal shunt with suspected shunt malfunction. See **Macrocephaly, Microcephaly, and Hydrocephalus (PEDHD-7)** for additional imaging.
- MRI Brain without contrast (CPT® 70551) or without and with contrast (CPT® 70553) is appropriate if a recent CT is inconclusive.
- MRI Brain without and with contrast (CPT® 70553) is appropriate if an abnormality is identified on a noncontrasted MRI performed greater than 2 weeks, otherwise a MRI Brain with contrast (CPT® 70552) is appropriate
- MRA Head or CTA Head are not generally medically necessary in the evaluation of headache in children unless a vascular lesion has been seen or suspected on a prior MRI Brain or CT Head.
 - ◆ Concurrent MRI and MRA is generally not indicated.
- MRV Head (CPT® 70544, CPT® 70545, or CPT® 70546) is indicated in pediatric individuals with papilledema and headache. See **Papilledema/Pseudotumor Cerebri (HD-17)** in the Head Imaging Guidelines.

References

1. Expert Panel on Pediatric Imaging; Hayes LL, Palasis S, et al. ACR Appropriateness Criteria® Headache-Child. J Am Coll Radiol. 2018;15(5S):S78-S90. doi:10.1016/j.jacr.2018.03.017
2. Expert Panel on Pediatric Imaging, Ryan ME, Pruthi S, et al. ACR Appropriateness Criteria® Head Trauma-Child. J Am Coll Radiol. 2020;17(5S):S125-S137. doi:10.1016/j.jacr.2020.01.026
3. Blume HK. Pediatric headache: a review. Pediatr Rev. 2012 Dec; 33: 562-574.
4. De Vries A, Young PC, Wall E, et al. CT scan utilization patterns in pediatric patients with recurrent headache. Pediatrics. 2013 July; 132 (1); e1-e8.
5. Lewis DW, Ashwal S, Dahl G, et al. Practice parameter: Evaluation of children and adolescents with recurrent headache. Neurology. 2002 Aug 27; 59 (4):490-498.
6. Trofimova A, Vey BL, Mullins ME, Wolf DS, Kadom N. Imaging of Children With Nontraumatic Headaches. American Journal of Roentgenology, 2018;210(1), 8-17.
7. Dao JM, Qubty W. Headache Diagnosis in Children and Adolescents. Current Pain and Headache Reports. 2018;22(3).
8. Bear JJ, Gelfand AA, Goadsby PJ, Bass N. Occipital headaches and neuroimaging in children. Neurology. 2017;89(5):469-474
9. Loder E, Weizenbaum E, Frishberg B, Silberstein S. Choosing Wisely in Headache Medicine: The American Headache Societys List of Five Things Physicians and Patients Should Question. Headache: The Journal of Head and Face Pain. 2013;53(10):1651-1659. doi:10.1111/head.12233.
10. Lewis DW, Ashwal S, Dahl G, et al; Quality Standards Subcommittee of the American Academy of Neurology; Practice Committee of the Child Neurology Society. Practice parameter: evaluation of children and adolescents with recurrent headaches—report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2002; 59:490-498.
11. Gofshteyn JS, Stephenson DJ. Diagnosis and Management of Childhood Headache. Current Problems in Pediatric and Adolescent Health Care. 2016;46(2):36-51. doi:10.1016/j.cppeds.2015.11.003.
12. Dalvi N, Sivaswamy L. Life-Threatening Headaches in Children: Clinical Approach and Therapeutic Options. Pediatric Annals. 2018;47(2). doi:10.3928/19382359-20180129-04.
13. Klein J, Koch T. Headache in Children. Pediatrics in Review. 2020;41(4):159-171. doi:10.1542/pir.2017-0012.
14. Sarma A, Poussaint TY. Indications and Imaging Modality of Choice in Pediatric Headache. Neuroimaging Clin N Am. 2019;29(2):271-289. doi:10.1016/j.nic.2019.01.007
15. Kadom N. Imaging of Headaches: Appropriateness and Differential Diagnosis. Pediatr Ann. 2020;49(9):e389-e394. doi:10.3928/19382359-20200819-01

Pediatric Head and Face Trauma (PEDHD-4)

Head Trauma (PEDHD-4.1)	20
Facial Trauma (PEDHD-4.2)	21

Head Trauma (PEDHD-4.1)

- In individuals with recent head trauma, a history focused on the incident and careful examination of the head, neck, and neurological function should be performed since the onset or change in signs and/or symptoms prior to considering advanced imaging.
- Advanced imaging is indicated for children with head trauma with ANY of the following red flags:
 - ◆ Loss of consciousness
 - ◆ Altered mental status or abnormal behavior
 - ◆ Known or suspected skull fracture
 - ◆ Glasgow Coma Score <15
 - ◆ Age younger than 2 years
 - ◆ Vomiting
 - ◆ Severe mechanism of injury
 - ◆ Severe or worsening headache
 - ◆ Amnesia
 - ◆ Nonfrontal scalp hematoma
- CT Head without contrast (CPT® 70450) is the primary advanced imaging study in individuals with acute head trauma.
 - ◆ CT Maxillofacial without contrast (CPT® 70486), CT Orbits/Temporal Bone without contrast (CPT® 70480), or CT Cervical Spine without contrast (CPT® 72125) is indicated if there has been associated injury to those structures.
- MRI Brain without contrast (CPT® 70551) is indicated for the following:
 - ◆ Children with an abnormal neurological exam that is not explained by the CT findings.
 - ◆ Subacute (8 days to one month after initial traumatic event) or chronic blunt head trauma with new or worsening neurological signs or cognitive symptoms
 - ◆ Children suspected of being the victims of physical abuse. See **Suspected Physical Child Abuse (PEDMS-7)** in the Pediatric Musculoskeletal Imaging Guidelines.
- Following a head injury, a repeat CT Head without contrast (CPT® 70450) or MRI Brain without contrast (CPT® 70551) is indicated if the child develops fixed or fluctuating diminished mental acuity or alertness, or new abnormalities on neurological examination.
- Follow-up of known or treated parenchymal subdural or epidural hematoma may require frequent imaging during the initial 8 weeks following injury, and these requests should generally be appropriate.

Facial Trauma (PEDHD-4.2)

- CT Maxillofacial without contrast (CPT® 70486) is the preferred imaging study in facial trauma.

Coding of Facial Imaging

- Both CT Orbital/Facial Bone (CPT® 70480) and CT Maxillofacial (CPT® 70486) cover the structures of the orbits, sinuses, and face. Unless there is a grounded suspicion of simultaneous involvement of more posterior lesions, especially of the region involving the middle or inner ear, one of these studies only should be sufficient.
- CT Maxillofacial (CPT® 70486) is the usual study (except in obvious orbital or temporal bone trauma), but either study is appropriate.

References

1. Expert Panel on Pediatric Imaging, Ryan ME, Pruthi S, et al. ACR Appropriateness Criteria® Head Trauma-Child. J Am Coll Radiol. 2020;17(5S):S125-S137. doi:10.1016/j.jacr.2020.01.026
2. Osmond MH, Klassen TP, Wells GA, et al. CATCH: a clinical decision rule for the use of computed tomography in children with minor head injury. CMAJ. 2010 Mar 9; 182 (4): 341-348.
3. Nigrovic LE, Stack AM, Mannix RC, et al. Quality improvement effort to reduce Cranial CTs for children with minor blunt head trauma. Pediatrics. 2015; 136 (1): e227-e233.
4. Homme J(JL. Pediatric Minor Head Injury 2.0. Emergency Medicine Clinics of North America. 2018;36(2):287-304.
5. Lumba-Brown A, Yeates KO, Sarmiento K, et al. Centers for Disease Control and Prevention Guideline on the Diagnosis and Management of Mild Traumatic Brain Injury Among Children. JAMA Pediatr. 2018;172(11):e182853. doi:10.1001/jamapediatrics.2018.2853.
6. Babl FE, Borland ML, Phillips N, Kochar A, Dalton S, McCaskill M, Cheek JA, Gilhotra Y, Furyk J, Neutze J, Lyttle MD. Accuracy of PECARN, CATCH, and CHALICE head injury decision rules in children: a prospective cohort study. The Lancet. 2017 Jun 17;389(10087):2393-402.
7. O'Brien WT, Caré MM, Leach JL. Pediatric Emergencies: Imaging of Pediatric Head Trauma. Seminars in Ultrasound, CT and MRI. 2018;39(5):495-514. doi:10.1053/j.sult.2018.01.007.
8. Schachar JL, Zampolin RL, Miller TS, Farinhas JM, Freeman K, Taragin BH. External validation of the New Orleans Criteria (NOC), the Canadian CT Head Rule (CCHR) and the National Emergency X-Radiography Utilization Study II (NEXUS II) for CT scanning in pediatric patients with minor head injury in a non-trauma center. Pediatric Radiology. 2011;41(8):971-979. doi:10.1007/s00247-011-2032-4.
9. Taylor CA, Bell JM, Breiding MJ, Xu L. Traumatic Brain Injury–Related Emergency Department Visits, Hospitalizations, and Deaths — United States, 2007 and 2013. MMWR Surveillance Summaries. 2017;66(9):1-16. doi:10.15585/mmwr.ss6609a1.
10. Kuppermann N, Holmes JF, Dayan PS, et al. Identification of children at very low risk of clinically-important brain injuries after head trauma: a prospective cohort study. The Lancet. 2009;374(9696):1160-1170. doi:10.1016/s0140-6736(09)61558-0.
11. Kochanek PM and Bell MJ. Neurologic Emergencies and Stabilization. Nelson Textbook of Pediatrics, Chapter 85. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21st edition 2020, 21st edition. 2020, pp 557-563.
12. Easter JS, Bakes K, Dhaliwal J, Miller M, Caruso E, Haukoos JS. Comparison of PECARN, CATCH, and CHALICE Rules for Children With Minor Head Injury: A Prospective Cohort Study. Annals of Emergency Medicine. 2014;64(2). doi:10.1016/j.annemergmed.2014.01.030.
13. Harmon KG, Clugston JR, Dec K, et al. American Medical Society for Sports Medicine position statement on concussion in sport. British Journal of Sports Medicine. 2019;53(4):213-225. doi:10.1136/bjsports-2018-100338.
14. ACR-ASNR-SPR Practice Parameter for the Performance of Computed Tomography (CT) of the Extracranial Head and Neck Revised 2021. (Resolution 5). <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/CT-Head-Neck>
15. Gelineau-Morel RN, Zinkus TP, Le Pichon JB. Pediatric Head Trauma: A Review and Update. Pediatr Rev. 2019;40(9):468-481. doi:10.1542/pir.2018-0257

Sinus and Facial Imaging (PEDHD-5)	
General Considerations (PEDHD-5.1)	23
Imaging Indications in Sinusitis (PEDHD-5.2)	23
Stereotactic CT Localization (CPT® 77011) (PEDHD-5.3)	24
Requests for both Head and Sinus Imaging (PEDHD-5.4)	24
Allergic Rhinitis (PEDHD-5.5)	25
Other Indications for Sinus Imaging (PEDHD-5.6)	25

General Considerations (PEDHD-5.1)

- Acute sinusitis is a clinical diagnosis, and imaging is not indicated to establish a diagnosis. Acute bacterial sinusitis can be presumptively diagnosed in a child with acute upper respiratory infection (URI) symptoms and any of the following:
 - ◆ Persistent symptoms lasting >10 days without improvement.
 - ◆ Worsening symptoms after initial period of improvement.
 - ◆ Severe symptoms including purulent nasal discharge and fever >102.2°F for at least 3 consecutive days.
 - ◆ Presumed bacterial infections should be treated empirically with appropriate antibiotics.
 - ◆ Imaging of any kind cannot distinguish bacterial from viral sinusitis.

Imaging Indications in Sinusitis (PEDHD-5.2)

- Mild mucosal thickening in the paranasal sinuses or mastoids is an extremely common incidental finding noted on head imaging studies done for other indications. If there are no other abnormalities of facial structures noted, this finding is not an indication for advanced imaging of the sinuses or temporal bone.
- CT Maxillofacial without contrast (CPT® 70486) is indicated if ANY of the following is present:
 - ◆ No improvement after 10 days of appropriate antibiotic treatment
 - Generally this will be amoxicillin/clavulanate, amoxicillin, cefdinir, cefuroxime, cefpodoxime, or ceftriaxone
 - ◆ Recurrence of a treated infection within 8 weeks of effective treatment
 - ◆ Chronic sinusitis (persistent residual URI symptoms for >90 days)
 - ◆ Known or suspected fungal sinusitis (MRI Orbit, Face, and/or Neck without and with contrast (CPT® 70543) is appropriate if requested instead of CT Maxillofacial)
 - ◆ Preoperative evaluation to assess surgical candidacy
- CT Maxillofacial with contrast (CPT® 70487) can be performed if ANY of the following is present:
 - ◆ Orbital or facial cellulitis
 - ◆ Proptosis
 - ◆ Abnormal visual examination
 - ◆ Ophthalmoplegia
 - ◆ Cystic fibrosis
 - ◆ Immunocompromised individual
 - ◆ Fungal or vascular lesions visualized in nasal cavity
- CT Head with contrast (CPT® 70460) or MRI Brain without and with contrast (CPT® 70553) or MRI Orbit, Face and/or Neck with and without contrast (CPT® 70543) is indicated if ANY of the following are present:
 - ◆ Focal neurologic findings
 - ◆ Altered mental status
 - ◆ Seizures
 - ◆ Concern for orbital complications
 - ◆ Concern for invasive fungal sinusitis

- ◆ MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546) or CTA Head (CPT® 70496) is appropriate with these findings as well if there is clinical concern for associated vascular complications including but not limited to mycotic aneurysm or venous sinus thrombosis.
- Repeat sinus imaging is generally not indicated for individuals who have responded satisfactorily to treatment, but is appropriate with clear documentation of the need for updated CT results to direct acute patient care decisions.

Stereotactic CT Localization (CPT® 77011) (PEDHD-5.3)

- Stereotactic CT localization is frequently obtained prior to sinus surgery. The dataset is then loaded into the navigational workstation in the operating room for use during the surgical procedure. The information provides exact positioning of surgical instruments with regard to the individual's 3D CT images. In most cases, the preoperative CT is a technical-only service that does not require interpretation by a radiologist.
- For treatment planning for sinus surgery CPT® 77011: A stereotactic CT localization scan is frequently obtained prior to sinus surgery. The dataset is then loaded into the navigational workstation in the operating room for use during the surgical procedure. The imaging facility should report CPT® 77011 when performing a scan not requiring interpretation by a radiologist.
- If a diagnostic scan is performed and interpreted by a radiologist, the appropriate diagnostic CT code (e.g. CPT® 70486) should be used.
- It is not appropriate to report both CPT® 70486 and CPT® 77011 for the same CT stereotactic localization imaging session.
- 3D Rendering (CPT® 76376 or CPT® 76377) should not be reported in conjunction with CPT® 77011 (or CPT® 70486 if used). The procedure inherently generates a 3D dataset.
- Such operative studies are indicated when ordered by the operating surgeon for this purpose.

Requests for both Head and Sinus Imaging (PEDHD-5.4)

- CT Head does not visualize all of the sinuses.
- MRI Brain provides excellent visualization of the sinuses sufficient to recognize sinusitis, and addition of sinus CT for this purpose is unnecessary.
- In individuals being evaluated for potential sinus surgery, separate CT Sinus is often appropriate even after a MRI Brain in order to visualize obstructions to spontaneous mucus flow. See **Stereotactic CT Localization (CPT® 77011) (PEDHD-5.3)**.
- Separate head imaging is not generally indicated in individuals with a normal neurological examination who have headaches associated with sinus symptoms.
- CT or MRI Sinus is not indicated for the evaluation of headaches or neurological complaints without a more specific indication pointing to a sinus etiology.

Allergic Rhinitis (PEDHD-5.5)

- Advanced imaging is not indicated for diagnosis or management of individuals with uncomplicated allergic rhinitis.

Other Indications for Sinus Imaging (PEDHD-5.6)

- See **Facial Trauma (PEDHD-4.2)** for imaging guidelines in trauma.
- CT Maxillofacial without contrast (CPT® 70486) - Congenital anomalies of facial structures.
- Cleft lip and palate can be associated with brain malformations and abnormal brain development. MRI Brain (CPT® 70551) is appropriate in cases of cleft lip and/or palate. See **Cleft Palate (PEDHD-8.2)**
- 3D CT reconstructed images (CPT® 76377) in conjunction with routine CT should be an integral part of the examination in evaluating craniofacial abnormalities.
- CT Maxillofacial without and with contrast (CPT® 70488) or MRI Orbits/Face/Neck without and with contrast (CPT® 70543) - Tumors or other disorders of facial structures.
- Obstructive sleep apnea See **Pediatric Sleep Disorders (PEDHD-24.1)** for imaging guidelines.
- See **Sinus and Facial Imaging (HD-29)** for conditions not addressed in Sinus and Facial Imaging (PEDHD-5)

References

1. Wald ER, Applegate KE, Bordley C, et al. Clinical Practice Guideline for the Diagnosis and Management of Acute Bacterial Sinusitis in Children Aged 1 to 18 Years. PEDIATRICS. 2013;132(1):e262-e280. doi:10.1542/peds.2013-1071
2. Expert Panel on Pediatric Imaging; Tekes A, Palasis S, et al. ACR Appropriateness Criteria® Sinusitis-Child. J Am Coll Radiol. 2018;15(11S):S403-S412. doi:10.1016/j.jacr.2018.09.029.
3. Pappas DE, and Hendley JO. Sinusitis. Nelson Textbook of Pediatrics, Chapter 408. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker, RC, Wilson KM. 21st edition. 2020, pp 2188-2192.
4. Magit A. Pediatric Rhinosinusitis. Otolaryngologic Clinics of North America. 2014;47(5):733-746. doi:10.1016/j.otc.2014.06.003
5. Siedman MD, Gurgel RK, Lin SY, et al. Clinical Practice Guideline. Otolaryngology–Head and Neck Surgery. 2015;152(2):197-206. doi:10.1177/0194599814562166
6. AAP Releases Guideline on Diagnosis and Management of Acute Bacterial Sinusitis in Children One to 18 Years of Age. Am Fam Physician. 2014 Apr 15;89:676-681.
7. ACR-ASNR-SPR Practice Parameter for the Performance of Computed Tomography (CT) of the Extracranial Head and Neck Revised 2021. (Resolution 5). <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/CT-Head-Neck>.
8. Gallagher ER, Collett BR. Neurodevelopmental and Academic Outcomes in Children With Orofacial Clefts: A Systematic Review. Pediatrics. 2019;144(1):e20184027. doi:10.1542/peds.2018-4027
9. Ornoy, A. Craniofacial malformations and their association with brain development: the importance of a multidisciplinary approach for treatment. Odontology. 2019;108(1):1-15. doi:10.1007/s10266-019-00433-7.
10. Kucukguven A, Calis M, Topaloglu H, Ozgur F. Assessment of Neurologic Disorders and Rare Intracranial Anomalies Associated With Cleft Lip and Palate. Journal of Craniofacial Surgery. 2018;29(8):2195-2197. doi:10.1097/scs.0000000000004848.

Epilepsy and Other Seizure Disorders (PEDHD-6)

Epilepsy and Other Seizure Disorders (PEDHD-6.0)	27
Initial Imaging of Non-Febrile Seizures (PEDHD-6.1)	27
Repeat imaging indications (PEDHD-6.2)	28
Special Imaging Studies in Evaluation for Epilepsy Surgery (PEDHD-6.3)	28
Febrile Seizures (PEDHD-6.4)	30

Epilepsy and Other Seizure Disorders (PEDHD-6.0)

- A pertinent evaluation including a detailed history, physical examination with a thorough neurologic examination, since the onset or change in signs and/or symptoms, and appropriate laboratory studies should be performed prior to considering the use of an advanced imaging (CT, MRI, Nuclear Medicine) procedure. An exception can be made if the individual is undergoing guideline-supported, scheduled follow-up imaging evaluation or request is from or in consultation with a neurologist or neurosurgeon who has seen the individual since onset of symptoms. This clinical evaluation should also include family history and (whenever possible) the accounts of eyewitnesses to the event(s).

Initial Imaging of Non-Febrile Seizures (PEDHD-6.1)

- MRI Brain without contrast (CPT® 70551) or without and with contrast (CPT® 70553) is indicated for the following:
 - ◆ First-time seizure in child that has no known cause and is not associated with fever
 - ◆ Partial seizures
 - ◆ New onset primary generalized epilepsy (e.g., absence epilepsy or juvenile myoclonic epilepsy)¹ in those who are neurologically abnormal, (e.g. developmental delay)
 - ◆ Focal neurologic deficits
 - ◆ Inconclusive findings on recent cranial ultrasound or CT Head
 - If individual meets criteria for MRI imaging for initial imaging of non-febrile seizure, MRI is appropriate even with a recent negative CT.
 - ◆ MRI Brain with and without contrast (CPT® 70553) is appropriate if there are history or examination findings concerning for a mass lesion or demyelinating disease.
- CT Head without contrast (CPT® 70450) is indicated for the following:
 - ◆ First-time seizure in child associated with recent head trauma, barrier to obtaining a neuroimaging study in a timely manner and should not preclude MRI imaging when requested. (Late post traumatic seizures may be better evaluated by MRI Brain without contrast (CPT® 70551) See **Head Trauma (PEDHD-4.1)**).
 - ◆ Individual cannot safely undergo MRI (avoidance of sedation is not an indication) or in urgent situations.
 - ◆ Identification of blood and calcifications
- Cranial ultrasound (CPT® 76506) for the following:
 - ◆ First-time seizure in child <30 days of age that has no known cause and is not associated with fever if the infant has an open fontanelle.
 - ◆ Cranial ultrasound is not required before MRI Brain without (CPT® 70551) for hypoxic ischemic encephalopathy (HIE) and congenital malformations.
- The following imaging tests do not generally add valuable information initially and are not indicated for the initial evaluation of seizures in children:
 - ◆ CTA Head or Neck
 - ◆ MRA Head or Neck
 - ◆ MRI Cervical, Thoracic, or Lumbar Spine

Repeat imaging indications (PEDHD-6.2)

- Repeat MRI Brain without contrast (CPT® 70551) or without and with contrast (CPT® 70553) is indicated for the following:
 - ◆ Need to perform MRI using Epilepsy Protocol (typically 3T magnet with thin section angled slices through hippocampus and temporal lobes, either without or without and with contrast)
 - ◆ New or worsening focal neurologic deficits
 - ◆ Refractory or drug resistant seizures (See Background and Supporting Information below)
 - ◆ Change in seizure type
 - ◆ Repeat imaging for persistent seizures as per specialist request or any provider in consultation with a specialist
 - ◆ MRI Brain with contrast (CPT® 70552) or without or with contrast (CPT® 70553) to clarify an abnormality on noncontrast MRI or if considering infection or inflammation

Background and Supporting Information

Drug Resistant synonyms may include “Refractory”, “Intractable” or “Pharmacoresistant”
Drug Resistant requires only 2 trials of antiepileptic medications

Special Imaging Studies in Evaluation for Epilepsy Surgery (PEDHD-6.3)

- Individuals with a previous MRI Brain and documentation of intractable epilepsy for which surgical treatment or another interventional modality is under active consideration, below are examples of, but not all inclusive, include:
 - ◆ Focal Resection
 - ◆ Temporal Lobe Resection
 - ◆ Extratemporal Resection
 - ◆ Lesionectomy
 - ◆ Multiple Subpial Transections
 - ◆ Laser Interstitial Thermal Therapy
 - ◆ Anatomical or Functional Hemispherectomy and Hemispherotomy
 - ◆ Corpus Callosotomy
 - ◆ Stereotactic Radiosurgery
 - ◆ Neurostimulation Device Implantations including,
 - Vagus Nerve Stimulation (VNS)
 - Responsive Neurostimulation
 - Deep Brain Stimulation
- The following requests are appropriate for presurgical evaluation:
 - ◆ MRI Brain without contrast or with and without contrast 3T/7T (CPT® 70551 or CPT® 70553)
 - ◆ Ictal SPECT (CPT® 78803)
 - ◆ Functional MRI (f-MRI) (CPT® 70555 or CPT® 70554) See **Functional MRI (fMRI) (HD-24.2)** in the Head Imaging Guidelines

- ◆ Metabolic (FDG) PET Brain (CPT® 78608)
 - Metabolic (FDG) PET Brain/MRI is generally not supported for neurologic conditions due to lack of standardization in imaging technique and interpretation. However, it may be appropriate in certain pediatric individuals when ALL of the following criteria are met:
 - The individual meets guideline criteria for Metabolic (FDG) PET/CT Brain AND
 - Metabolic (FDG) PET/CT Brain is not available at the treating institution AND
 - The provider requests Metabolic (FDG) PET Brain/MRI in lieu of Metabolic (FDG) PET/CT Brain
 - Metabolic (FDG) PET Brain/MRI, when the above criteria are met, are reported using the code combination of Metabolic (FDG) PET Brain (CPT® 78608) and MRI Brain (CPT® 70551 or CPT® 70553). All other methods of reporting Metabolic (FDG) PET Brain/MRI are inappropriate.
 - When clinically appropriate, diagnostic MRI codes may be appropriate at the same time as the Metabolic (FDG) PET Brain/MRI code combination.
- ◆ MR Spectroscopy (CPT® 76390).
 - NOTE: Certain payors consider MR Spectroscopy investigational/experimental, and those coverage policies take precedence over eviCore Imaging Guidelines.
- ◆ See **Primary Central Nervous System Tumors-General Considerations (ONC-2.1)** in the Oncology Imaging Guidelines for additional imaging requests for surgery and/or **Neurosurgical Imaging (HD-28)** in the Head Imaging Guidelines
- When noninvasive EEG monitoring is insufficient, intracranial monitoring with stereo-EEG or grids/strips and electrodes may be required with appropriate additional imaging for neuronavigation with one of each of the following after consulting the health plan direction for unlisted codes:
 - ◆ MRI Brain with and without or without contrast (CPT® 70553 or CPT® 70551)
 - ◆ CT Head without or with contrast (CPT® 70450 or CPT® 70460)
 - ◆ If previous head imaging is considered inadequate or additional sequences/protocols are required OR is greater than 6 months old, diagnostic head imaging may be appropriate.
- Due to variances with techniques currently available for neuronavigation, the following are appropriate:
 - ◆ CTA Head without and with contrast (CPT® 70496) or MRA Head (CPT® 70544, CPT® 70545 or CPT® 70546)
 - ◆ Post-operative imaging including after intracranial (EEG) monitoring is appropriate per neurosurgeon's request.

Febrile Seizures (PEDHD-6.4)

- A typical febrile seizure is a generalized seizure occurring in the presence of fever (T >100.4°F/38°C) and no central nervous system infection in a child between the age of 6 months and 5 years.
- Neuroimaging should not be performed in the routine evaluation of children with simple febrile seizures.
- MRI Brain without contrast (CPT® 70551) or without and with contrast (CPT® 70553) is indicated for febrile seizures in the presence of one or more of the following:
 - ◆ Seizure lasting >15 minutes
 - ◆ Partial seizures
 - ◆ Focal neurologic deficits
 - ◆ Multiple seizures within 24 hours
 - ◆ Macrocephaly (Head circumference that is greater than the 95th percentile for age and sex, established by use of measurements and CDC growth charts. See **Macrocephaly (PEDHD-7.1)**)
 - ◆ Signs and symptoms of increased intracranial pressure
 - ◆ Developmental delay

References

1. Expert Panel on Pediatric Imaging, Trofimova A, Milla SS, et al. ACR Appropriateness Criteria® Seizures-Child. J Am Coll Radiol. 2021;18(5S):S199-S211. doi:10.1016/j.jacr.2021.02.020
2. Mikati MA, and Tchapyjnikov, D. Seizures in Childhood. Nelson Textbook of Pediatrics, Chapter 611. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker, RC, Wilson KM. 21st edition. 2020, pp 3086-3120.
3. Sidhu R, Velayudam K, and Barnes G. Pediatric seizures. Pediatr Rev. 2013 Aug; 34 (8):333-341.
4. Ramey WL, Martirosyan NL, Lieu CM, et al. Current management and surgical outcomes of medically intractable epilepsy. Clin Neurol Neurosurg. 2013 Dec; 115 (12):2411-2418.
5. Schuele SU. Evaluation of Seizure Etiology From Routine Testing to Genetic Evaluation. CONTINUUM: Lifelong Learning in Neurology. 2019;25(2):322-342. doi:10.1212/con.0000000000000723.
6. Duffner PK, Berman PH, Baumann RJ, et al. Clinical practice guideline—febrile seizures: guideline for the neurodiagnostic evaluation of the child with a simple febrile seizure. Pediatrics. 2011 Feb; 127 (2): 389-394.
7. Cendes F, Theodore WH, Brinkmann BH, et al. Neuroimaging of epilepsy. Handb Clin Neurol. 2016;136:985-1014. doi: 10.1016/B978-0-444-53486-6.00051-X.
8. Biassoni L, Easty M. Paediatric nuclear medicine imaging. British Medical Bulletin. 2017;123(1):127-148. doi:10.1093/bmb/idx025.
9. Coryell J, Gaillard WD, Shellhaas RA, et al. Neuroimaging of Early Life Epilepsy. Pediatrics. 2018;142(3). doi:10.1542/peds.2018-0672.
10. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies [published correction appears in Epilepsia. 2010 Sep;51(9):1922]. Epilepsia. 2010;51(6):1069-1077. doi:10.1111/j.1528-1167.2009.02397.x
11. Gaillard WD, Chiron C, Cross JH, et al. Guidelines for imaging infants and children with recent-onset epilepsy. Epilepsia. 2009;50(9):2147-2153. doi:10.1111/j.1528-1167.2009.02075.x.
12. Szaflarski JP, Gloss D, Binder JR, et al. Practice guideline summary: Use of fMRI in the presurgical evaluation of patients with epilepsy. Neurology. 2017;88(4):395-402. doi:10.1212/wnl.0000000000003532.
13. Duez L, Tankisi H, Hansen PO, et al. Electromagnetic source imaging in presurgical workup of patients with epilepsy. Neurology. 2019;92(6). doi:10.1212/wnl.0000000000006877.
14. Qiu J, Cui Y, Qi B, Sun L, Zhu Z. The application of preoperative computed tomography angiogram for hemispherectomy. Clinics and Practice. 2017;7(4). doi:10.4081/cp.2017.992.
15. Youngerman BE, Khan FA, Mckhann GM. Stereoelectroencephalography in epilepsy, cognitive neurophysiology, and psychiatric disease: safety, efficacy, and place in therapy. Neuropsychiatric Disease and Treatment. 2019;Volume 15:1701-1716. doi:10.2147/ndt.s177804/.
16. Iida K, Otsubo H. Stereoelectroencephalography: Indication and Efficacy. Neurologia medico-chirurgica. 2017;57(8):375-385. doi:10.2176/nmc.ra.2017-0008.
17. Yoo JY, Panov F. Identification and treatment of drug-resistant epilepsy. CONTINUUM: Lifelong Learning in Neurology. 2019 Apr 1;25(2):362-80. doi: 10.1212/CON.0000000000000710.
18. Orringer DA, Golby A, Jolesz F. Neuronavigation in the surgical management of brain tumors: current and future trends. Expert review of medical devices. 2012 Sep 1;9(5):491-500.

Macrocephaly, Microcephaly, and Hydrocephalus (PEDHD-7)

Macrocephaly (PEDHD-7.1)	32
Microcephaly (PEDHD-7.2)	32
Hydrocephalus (PEDHD-7.3)	32

Macrocephaly (PEDHD-7.1)

- Macrocephaly is defined as head circumference that is greater than the 95th percentile for age and sex, or head circumference increasing in percentiles over two visits established by use of measurements and CDC growth charts. An online calculator to determine head circumference percentile is available at: <http://www.infantchart.com/cdc0to3headforage.php>
- Birth to age 6 months:
 - ◆ Ultrasound Head (CPT® 76506) is indicated initially in individuals with an open fontanelle.
 - ◆ CT Head without contrast (CPT® 70450) is indicated if hydrocephalus or hemorrhage is present on ultrasound.
 - ◆ MRI Brain without contrast (CPT® 70551) or without and with contrast (CPT® 70553) is indicated for any abnormality seen on ultrasound.
- Age 7 months and older, or with closed fontanelle:
 - ◆ MRI Brain without contrast (CPT® 70551) or without and with contrast (CPT® 70553) is indicated.
 - ◆ CT is generally not indicated in this age group since uncomplicated hydrocephalus is less likely after early infancy.

Microcephaly (PEDHD-7.2)

- Microcephaly is defined as head circumference that is less than the 5th percentile for age and sex, or head circumference decreasing in percentiles over two visits established by use of measurements and CDC growth charts. An online calculator to determine head circumference percentile is available at: <http://www.infantchart.com/cdc0to3headforage.php>.
- MRI Brain without and with contrast (CPT® 70553) is indicated for all individuals.
 - ◆ CT is generally not recommended as that modality lacks the sensitivity to detect the relevant anatomical abnormalities.

Hydrocephalus (PEDHD-7.3)

- This is the most common identifiable cause of macrocephaly. Almost all hydrocephalus is obstructive, except hydrocephalus due to choroid plexus papillomas. See **Choroid Plexus Tumors (PEDONC-4.13)** in the Pediatric Oncology Imaging Guidelines for those lesions.
- Hydrocephalus is traditionally divided into non-communicating (the obstruction lies within the course of the brain's ventricular system) and communicating (the obstruction is distal to the ventricular system).
- Ventriculomegaly refers to enlarged ventricular spaces. It is often initially found on fetal ultrasound. It can be from an obstructive cause or can be relative secondary to small brain volume. It can remain stable and may be monitored with serial ultrasound (CPT® 76506) to assess stability or MRI Brain with and without contrast (CPT® 70553) if over age 6 months. If ventriculomegaly progresses to hydrocephalus, follow imaging timelines listed below for hydrocephalus.

- Benign external hydrocephalus (aka benign extra-axial fluid collection among other names) is defined as a rapid increase in head circumference in an infant with enlarged frontal subarachnoid spaces. It is a common cause of macrocephalus and is commonly secondary to a familial large head size. See **Macrocephaly (PEDHD-7.1)** for initial imaging guidelines. It typically requires no intervention. Once diagnosed and confirmed with MRI Brain with and without contrast (CPT® 70553) no additional imaging is required unless new neurological symptoms appear, worsen or persist beyond age 4 years. If developmental motor delay See **Developmental Motor Delay (PEDHD 19.3)**
- For CSF flow imaging See **CSF Flow Imaging (HD-24.4)** in the Head Imaging Guidelines

Initial Imaging Indications:

- **Age 0-6 months:**
 - ◆ Screening head ultrasound examination (CPT® 76506)
 - ◆ MRI Brain without and with contrast (CPT® 70553) is indicated if ultrasound shows hydrocephalus.
 - ◆ Serial US (CPT® 76506) can be used to monitor ventricular size to determine need and timing of placement of a ventricular catheter, or performance of an endoscopic third ventriculostomy (ETV)
- **Greater than 6 months old:**
 - ◆ MRI Brain without and with contrast (CPT® 70553) is indicated.
- **Spine imaging:**
 - ◆ MRI Spine without and with contrast (CPT® 72156, CPT® 72157, and CPT® 72158) may be indicated in individuals with Chiari malformation (multiple spine segments), Dandy-Walker malformation (cervical spine only), or malignant infiltration of the meninges.

Repeat Imaging Indications including CSF flow shunting and Ventriculostomy

- Rapid MRI Brain without contrast (CPT® 70551) or CT Head without contrast (CPT® 70450) is indicated for any new signs or symptoms suggesting shunt malfunction, or ETV malfunction, including (but not limited to) sepsis, decreased level of consciousness, protracted vomiting, visual or neurologic deterioration, decline of mentation after initial improvement, or new or changing pattern of seizures.
- Rapid MRI Brain without contrast (CPT® 70551) or CT Head without contrast (CPT® 70450) is indicated after shunt setting adjustments or as ordered by a specialist (neurologist or neurosurgeon) or any provider in consultation with a specialist.
- Rapid MRI Brain without contrast (CPT® 70551) or CT Head without contrast (CPT® 70450) is indicated in the postoperative period following shunt placement or ETV, with further follow-up imaging 6-12 months after the procedure and then every 12 months for individuals with stable clinical findings.
 - ◆ Rapid MRI provides more anatomical detail and does not involve radiation exposure, but many providers use CT Head as rapid MRI is not universally available.
 - ◆ For routine follow up imaging with CT a low dose protocol should be used.

- Shunting into the peritoneum (VP shunts) can give rise to abdominal complications, but these are generally symptomatic, so surveillance imaging of the abdomen is not indicated.
 - ◆ Abdominal ultrasound (CPT® 76700) is appropriate for suspicion of CSF pseudocyst formation or distal shunt outlet obstruction.
- Familial screening is not indicated for hydrocephalus except in siblings of individuals with aqueductal stenosis, for whom a one-time CT Head without contrast (CPT® 70450) or Rapid MRI Brain without contrast (CPT® 70551) is indicated.

Additional Rarely Used Studies:

- Cisternogram (CPT® 78630) is rarely done in children but can be appropriate for the following:
 - ◆ Known hydrocephalus with worsening symptoms.
 - ◆ Suspected obstructive hydrocephalus.
 - ◆ Suspected normal pressure hydrocephalus with gait disturbance and either dementia or urinary incontinence.
- Cerebrospinal Ventriculography (CPT® 78635) is rarely done in children but can be appropriate for the following:
 - ◆ Evaluation of internal shunt, porencephalic cyst, or posterior fossa cyst.
- Nuclear Medicine Shunt Evaluation (CPT® 78645) and CSF Flow SPECT (CPT® 78803) are rarely done in children but can be appropriate for the following:
 - ◆ Suspected malfunction of ventriculoperitoneal, ventriculopleural, or ventriculovenous shunts.

Background and Supporting Information

- Head ultrasound can be performed while the fontanelles are still open and has excellent spatial and anatomic resolution, particularly within the first 2 months of life. After 6 months, smaller acoustic windows due to closing sutures limit the sensitivity of the examination

References

1. Ashwal S, Michelson D, Plawner L, et al. Practice parameter: evaluation of the child with microcephaly (an evidence-based review). *Neurology*. 2009 Sep; 73: 887-897.
2. Kinsman SL, and Johnston MV. Hydrocephalus. *Nelson Textbook of Pediatrics, Chapter 591.11*. eds Kliegman RM, Stanton BF, St. Geme JW III, et al. 20th edition. 2016, pp 2814-2817.
3. Boyle TP, Paldino MJ, Kimia AA, et al. Comparison of Rapid Cranial MRI to CT for Ventricular Shunt Malfunction. *Pediatrics*. 2014 July; 134 (1): e47-e54.
4. Orrù E, Calloni SF, Tekes A, Huisman TAGM, Soares BP. The Child With Macrocephaly: Differential Diagnosis and Neuroimaging Findings. *American Journal of Roentgenology*. 2018;210(4):848-859.
5. Raybaud A. Hydrocephalus. In: Barkovich AJ, ed. *Pediatric Neuroimaging*, 6th ed. Philadelphia PA. Wolters Kluwer. 2019; 907-972.
6. Feng Z, Li Q, Gu J, Shen W. Update on Endoscopic Third Ventriculostomy in Children. *Pediatric Neurosurgery*. 2018;53(6):367-370. doi:10.1159/000491638.
7. Wright Z, Larrew TW, Eskandari R. Pediatric Hydrocephalus: Current State of Diagnosis and Treatment. *Pediatrics in Review*. 2016;37(11):478-490. doi:10.1542/pir.2015-0134.
8. Sanyal S, Duraisamy S, Garga UC. Magnetic Resonance Imaging of Brain in Evaluation of Floppy Children: A Case Series. *Iran J Child Neurol*. 2015 Fall;9(4):65-74.
9. Ali AS. Magnetic Resonance Imaging (MRI) Evaluation of Developmental Delay in Pediatric Patients. *Journal Of Clinical And Diagnostic Research*. 2015. doi:10.7860/jcdr/2015/11921.5478.
10. Khalatbari H, Parisi MT. Complications of CSF Shunts in Pediatrics: Functional Assessment With CSF Shunt Scintigraphy—Performance and Interpretation. *American Journal of Roentgenology*. 2020;215(6):1474-1489. doi:10.2214/ajr.20.22899.
11. Zahl SM, Egge A, Helseth E, Wester K. Benign external hydrocephalus: a review, with emphasis on management. *Neurosurgical Review*. 2011;34(4):417-432. doi:10.1007/s10143-011-0327-4.
12. Kestle JRW, Riva-Cambrin J. Prospective multicenter studies in pediatric hydrocephalus. *Journal of Neurosurgery: Pediatrics*. 2019;23(2):135-141. doi:10.3171/2018.10.peds18328.
13. Patel SK, Zamorano-Fernandez J, Nagaraj U, Bierbrauer KS, Mangano FT. Not all ventriculomegaly is created equal: diagnostic overview of fetal, neonatal and pediatric ventriculomegaly. *Child's Nervous System*. 2019;36(8):1681-1696. doi:10.1007/s00381-019-04384-w.

Craniosynostosis/Cleft Palate (PEDHD-8)	
Craniosynostosis Imaging (PEDHD-8.1)	37
Cleft Palate (PEDHD-8.2)	37

Craniosynostosis Imaging (PEDHD-8.1)

- Craniosynostosis is the premature closure of one or more cranial sutures, usually during infancy. Craniosynostosis may be caused by a genetic condition, such as Apert, Pfeiffer or Crouzon syndrome to name a few.¹⁸ Abnormal head shape **is the common clinical feature**.
- Skull x-rays and/or ultrasound should be obtained prior to considering advanced imaging. In cases of very strong consideration of craniosynostosis with surgical planning in progress, x-rays and/or ultrasound are not required.
- CT Head without contrast (CPT® 70450) is indicated in the diagnosis of craniosynostosis.
- 3D rendering (CPT® 76377) is indicated with the initial diagnostic CT to evaluate the extent of synostosis and determine surgical candidacy or for preoperative planning.
- CT Maxillofacial (CPT® 70486) and CT Orbits (CPT® 70480) without contrast are generally not necessary to evaluate individuals with craniosynostosis but are indicated if the craniosynostosis is part of a larger congenital defect which also involves the bones of the face or orbits.
- CT Maxillofacial (CPT® 70486) and/or CT Orbits (CPT® 70480) may be indicated in certain types of craniosynostosis and may be approved when ordered by surgical specialties or in consultation with surgical specialties during surgical evaluation and planning
- Ultrasound Head (CPT® 76506) can be approved as an alternative method of assessing sutural patency in neonates and infants when radiographs are indeterminate. If inconclusive or for pre-operative planning, CT with 3D rendering can be approved as discussed previously in this section.
- CT Head without contrast (CPT® 70450) may be performed postoperatively at the discretion of or in consultation with the specialist coordinating the individual's care.
- Positional plagiocephaly typically does NOT require advanced imaging.^{13,15,16}

Cleft Palate (PEDHD-8.2)

- Congenital anomalies of facial structures - CT Maxillofacial without contrast (CPT® 70486) or MRI Face, Orbits and/or Neck without contrast or with and without contrast (CPT® 70540 or CPT® 70543)¹⁹.
- Cleft lip and palate can be associated with brain malformations and abnormal brain development. MRI Brain (CPT® 70551) is appropriate in individuals with cleft lip and/or palate. MRI Face, Orbits and/or Neck without contrast or with and without contrast (CPT® 70540 or CPT® 70543)¹⁹ is appropriate if requested by surgeon or any provider in consultation with the surgeon.

References

1. Hall KM, Besachio DA, Moore MD, et al. Effectiveness of screening for craniosynostosis with ultrasound: a retrospective review. *Pediatr Radiol*. 2017; 47: 606-612.
2. Rozovsky K, Udjus K, Wilson N, et al. Cranial ultrasound as a first-line imaging examination for craniosynostosis. *Pediatrics* 2016. 137: e20152230
3. Kinsman SL, and Johnston MV. Craniosynostosis. *Nelson Textbook of Pediatrics, Chapter 609.12*. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. I. 21st edition. 2020, pp 3080-3082.
4. Fearon JA. Evidence-based medicine: craniosynostosis. *Plast Reconstr Surg*. 2014 May; 133 (5): 1261-1275.
5. Khanna P, Thapa M, Iyer R, Prasad S. Pictorial essay: The many faces of craniosynostosis. *Indian Journal of Radiology and Imaging*. 2011;21(1):49. doi:10.4103/0971-3026.76055.
6. Mathijssen IM. Guideline for Care of Patients With the Diagnoses of Craniosynostosis. *Journal of Craniofacial Surgery*. 2015;26(6):1735-1807. doi:10.1097/scs.0000000000002016.
7. Kim HJ, Roh HG, Lee IW. Craniosynostosis : Updates in Radiologic Diagnosis. *Journal of Korean Neurosurgical Society*. 2016;59(3):219. doi:10.3340/jkns.2016.59.3.219.
8. ACR-ASNR-SPR Practice Parameter for the Performance of Computed Tomography (CT) of the Extracranial Head and Neck Revised 2021. (Resolution 5). <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/CT-Head-Neck.pdf>.
9. AIUM Practice Parameter for the Performance of Neurosonography in Neonates and Infants. *J Ultrasound Med*. 2020;39(5):E57-E61. doi:10.1002/jum.15264.
10. Gallagher ER and Collett BR. Neurodevelopmental and Academic Outcomes in Children With Orofacial Clefts: A Systematic Review. *Pediatrics*. 2019;144(1).
11. Rozovsky K, Udjus K, Wilson N, Barrowman NJ, Simanovsky N, Miller E. Cranial ultrasound as a first-line imaging examination for craniosynostosis. *Pediatrics*. 2016 Feb 1;137(2)
12. Massimi L, Bianchi F, Frassanito P, Calandrelli R, Tamburrini G, Caldarelli M. Imaging in craniosynostosis: when and what?. *Childs Nerv Syst*. 2019;35(11):2055-2069. doi:10.1007/s00381-019-04278-x
13. Flannery AM, Tamber MS, Mazzola C, et al. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines for the Management of Patients With Positional Plagiocephaly: Executive Summary. *Neurosurgery*. 2016;79(5):623-624. doi:10.1227/NEU.0000000000001426
14. Linz C, Collmann H, Meyer-Marcotty P, et al. Occipital plagiocephaly: unilateral lambdoid synostosis versus positional plagiocephaly. *Arch Dis Child*. 2015;100(2):152-157. doi:10.1136/archdischild-2014-305944
15. Linz C, Kunz F, Böhm H, Schweitzer T. Positional Skull Deformities. *Dtsch Arztebl Int*. 2017;114(31-32):535-542. doi:10.3238/arztebl.2017.0535 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624275/pdf/Dtsch_Arztebl_Int-114-0535.pdf
16. Mazzola C, Baird LC, Bauer DF, et al. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline for the Diagnosis of Patients With Positional Plagiocephaly: The Role of Imaging. *Neurosurgery*. 2016;79(5):E625-E626. doi:10.1227/NEU.0000000000001427
17. Schweitzer T, Böhm H, Meyer-Marcotty P, Collmann H, Ernestus RI, Krauß J. Avoiding CT scans in children with single-suture craniosynostosis. *Childs Nerv Syst*. 2012;28(7):1077-1082. doi:10.1007/s00381-012-1721-0
18. Wenger T, Miller D, Evans K. FGFR Craniosynostosis Syndromes Overview. 1998 Oct 20 [Updated 2020 Apr 30]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. *GeneReviews®* [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2022. https://www.ncbi.nlm.nih.gov/books/NBK1455/pdf/Bookshelf_NBK1455.pdf
19. Abramson ZR, Peacock ZS, Cohen HL, Choudhri AF. Radiology of Cleft Lip and Palate: Imaging for the Prenatal Period and throughout Life. *Radiographics*. 2015;35(7):2053-2063. doi:10.1148/rg.2015150050.

Chiari and Skull Base Malformations (PEDHD-9)

Chiari I Malformations (PEDHD-9.1)	40
Chiari II Malformations (Arnold Chiari Malformation) (PEDHD-9.2)	40
Chiari III and IV Malformations (PEDHD-9.3)	41
Basilar Impression (PEDHD-9.4)	41
Platybasia (PEDHD-9.5)	41

Chiari I Malformations (PEDHD-9.1)

- MRI Brain without contrast (CPT® 70551) or without and with contrast (CPT® 70553) and MRI of the entire spine without contrast (CPT® 72141, CPT® 72146, CPT® 72148) or without and with contrast (CPT® 72156, CPT® 72157, CPT® 72158) is indicated for initial evaluation.
- For CSF flow imaging See **CSF Flow Imaging (HD-24.4)** in the Head Imaging Guidelines
- Repeat imaging may be approved at the discretion of or in consultation with the specialist coordinating the individual's care for this condition.
- Repeat MRI Brain without contrast (CPT® 70551) or without and with contrast (CPT® 70553) is indicated for individuals with a known Chiari I malformation when any of the following are present:
 - ◆ There are new or worsening signs or symptoms
 - ◆ A surgical procedure is actively being considered.
- Repeat MRI Spine imaging is not indicated for individuals with normal initial spine imaging unless there are new or worsening signs or symptoms from baseline that suggest spinal cord pathology.
- Repeat brain and spine imaging in individuals with Chiari I malformations and known syringomyelia or hydromyelia is highly individualized
- Familial screening is not indicated for Chiari I Malformations.

Background and Supporting Information

- This involves caudal displacement or herniation of the cerebellar tonsils. Chiari I may be associated with syringomyelia, and rarely with hydrocephalus. Most cases are asymptomatic and discovered incidentally on a head scan performed for another indication. When symptoms are present, they are usually nonspecific but can include headache, lower cranial nerve palsies or sleep apnea.

Chiari II Malformations (Arnold Chiari Malformation) (PEDHD-9.2)

- Ultrasound is the initial examination in infants to determine ventricular size and associated anomalies and to provide a baseline for follow up evaluation.
- MRI Brain without and with contrast (CPT® 70553) and MRI of the entire spine without and with contrast (CPT® 72156, CPT® 72157, CPT® 72158) is indicated for initial advanced imaging evaluation.
- Repeat brain and spine imaging in individuals with Chiari II malformations is highly individualized and is indicated at the discretion of or in consultation with the specialist coordinating the individual's care for this condition.
- Familial screening is not indicated for Chiari II Malformations.

Background and Supporting Information

- These malformations are more severe than Chiari I malformations. These individuals usually present at birth. Myelomeningocele is always present, and syringomyelia and hydrocephalus are extremely common.

Chiari III and IV Malformations (PEDHD-9.3)

- Repeat brain and spine imaging in individuals with Chiari III and IV malformations is highly individualized and is indicated at the discretion of or in consultation with the specialist coordinating the individual's care for this condition.
- Familial screening is not indicated for Chiari III or IV Malformations.

Background and Supporting Information

- Chiari III malformation includes cerebellar herniation into a high cervical myelomeningocele. Chiari IV malformation refers to complete cerebellar agenesis. Both Chiari III and IV malformations are noted at birth, and are rarely compatible with life.

Basilar Impression (PEDHD-9.4)

- MRI Brain (CPT® 70551) and Cervical Spine (CPT® 72141) without contrast are indicated.
- CT Head (CPT® 70450) and Cervical Spine (CPT® 72125) without contrast are also indicated if surgery is being considered.
- Basilar impression appears to be genetic, and one-time screening of first-degree relatives with MRI Brain without contrast (CPT® 70551) can be appropriate.

Background and Supporting Information

- Basilar impression involves malformation of the occipital bone in relation to C1-2 (cervical vertebrae 1 and 2). The top of the spinal cord is inside the posterior fossa and the foramen magnum is undersized. Over time, this can lead to brain stem and upper spinal cord compression. Basilar impression can also be associated with the Chiari malformation, producing very complex anatomical abnormalities.

Platybasia (PEDHD-9.5)

- MRI Brain without contrast (CPT® 70551) or CT Head without contrast (CPT® 70450) is indicated to establish a diagnosis when clinically suspected, individuals are usually asymptomatic.

Background and Supporting Information

- Platybasia is a flattening malformation of the skull base, in which the clivus has a horizontal orientation.

References

1. Siegel MJ. Brain. In: pediatric sonography. 5th ed. Philadelphia. Wolters Kluwer. 2018. 40-111.
2. Mistovich, RJ and Spiegel, DA. Cervical Anomalies and Instabilities. Nelson Textbook of Pediatrics, Chapter 700.3. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21st edition. 2020, pp 3649-3650.
3. Strahle J, Muraszko KM, Kapurch J, et al. Chiari malformation Type I and syrinx in children undergoing magnetic resonance imaging. *J Neurosurg Pediatr.* 2011 Aug; 8 (2): 205-213.
4. Strahle J, Muraszko KM, Kapurch J, et al. Natural history of Chiari malformation Type I following decision for conservative treatment. *J Neurosurg Pediatr.* 2011 Aug; 8 (2): 214-221.
5. Strahle J, Muraszko KM, Garton HJL, et al. Syrinx location and size according to etiology: identification of Chiari-associated syrinx. *J Neurosurg Pediatr.* 2015 July; 16 (1): 21-9 Epub 2015 Apr 3.
6. Strahle J, Smith BW, Martinez M, et al. The association between Chiari malformation Type I, spinal syrinx, and scoliosis. *J Neurosurg Pediatr.* 2015 Jun; 15 (6): 607-611.
7. Smoker WRK and Khanna G. Imaging the craniocervical junction. *Childs Nerv Syst.* 2008 Oct; 24 (10): 1123-1145.
8. Victorio MC, Khoury CK. Headache and Chiari I Malformation in Children and Adolescents. *Seminars in Pediatric Neurology.* 2016;23(1):35-39.
9. Radic JAE, Cochrane DD. Choosing Wisely Canada: Pediatric Neurosurgery Recommendations. *Paediatrics & Child Health.* 2018;23(6):383-387. doi:10.1093/pch/pxy012.
10. Kinsman SL and Johnston MV. Congenital anomalies of the central nervous system. Nelson Textbook of Pediatrics, Chapter 609. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21st edition. 2020, pp 3063-3082
11. D'Arco F, Ganau M. Which neuroimaging techniques are really needed in Chiari I? A short guide for radiologists and clinicians. *Childs Nerv Syst.* 2019 Oct;35(10):1801-1808. doi: 10.1007/s00381-019-04210-3.

Intracranial Aneurysms and AVM (PEDHD-10)	
Pediatric Intracranial Aneurysms (PEDHD-10.1)	44
Pediatric Intracranial Arteriovenous Malformations (AVM) (PEDHD-10.2)	45

Pediatric Intracranial Aneurysms (PEDHD-10.1)

- Unlike adults, the majority of pediatric aneurysms are caused by genetic or developmental defects rather than environmental or lifestyle factors.
- Pediatric aneurysms most commonly present with subarachnoid hemorrhage, headache, increased intracranial pressure, seizure activity, or focal neurologic findings.
- A pertinent evaluation including a detailed history, physical examination with a thorough neurologic examination, and appropriate laboratory studies should be performed prior to considering advanced imaging, unless the individual is undergoing guideline-supported scheduled follow-up imaging evaluation or request is from a neurologist or neurosurgeon who has seen the individual since onset of symptoms.
- CT Head without contrast (CPT® 70450) or MRI Brain without contrast (CPT® 70551) is indicated as an initial study for individuals presenting with suspected subarachnoid hemorrhage.
 - ◆ CTA Head (CPT® 70496) or MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546) is indicated if subarachnoid hemorrhage is present on CT or MRI, or lumbar puncture findings suggest hemorrhage.
 - ◆ CT or MRI Perfusion See **General Guidelines-Other Imaging Situations (PEDHD-1.4)**
- MRI Brain without and with contrast (CPT® 70553) is indicated as an initial study for individuals presenting with headache, increased intracranial pressure, seizures, or focal neurologic findings.
 - ◆ CTA Head (CPT® 70496) or MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546) is indicated if findings suspicious for intracranial aneurysm are present on MRI.
- MRI Brain without contrast (CPT® 70551) or without and with contrast (CPT® 70553) and MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546) are indicated for individuals with known unruptured aneurysm presenting with headache, increased intracranial pressure, seizures, or focal neurologic findings.
- CTA Head (CPT® 70496) for individuals with treated aneurysms is preferred.
- MRI Brain without contrast (CPT® 70551) or without and with contrast (CPT® 70553) and MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546) are indicated for individuals with any of the following conditions and headache, increased intracranial pressure, seizures, or focal neurologic findings:
 - ◆ Polycystic kidney disease
 - ◆ Fibromuscular dysplasia
 - ◆ Ehlers-Danlos Syndrome
 - ◆ Klippel-Trenaunay-Weber Syndrome
 - ◆ Tuberous Sclerosis
 - ◆ Moyamoya Syndrome
 - ◆ Hereditary Hemorrhagic Telangiectasia (Osler-Weber-Rendu Syndrome)
 - ◆ Pseudoxanthoma elasticum
 - ◆ Neurofibromatosis type 1
 - ◆ Kawasaki disease

- ◆ Coarctation of the aorta
- ◆ Patent ductus arteriosus
- ◆ Hyper-IgE syndrome
- ◆ 4 forms of Loeys-Dietz syndrome
- ◆ Klinefelter syndrome
- ◆ Alpha-glucosidase deficiency
- ◆ Noonan syndrome
- ◆ Pheochromocytoma
- ◆ Alpha-1-antitrypsin deficiency
- ◆ Presence of an azygos anterior cerebral artery
- ◆ Marfan Syndrome
- ◆ Bicuspid aortic valve
- ◆ Microcephalic osteodysplastic primordial dwarfism Type II
- The timing of follow-up imaging for intracranial aneurysms in children is similar to that in adults. See **Intracranial Aneurysms (HD-12.1)** in the Head Imaging Guidelines.
- Screening MRI Brain or MRA Head for aneurysms is not supported in asymptomatic individuals under age 20 since only 0.6% of ruptured aneurysms occur in the pediatric age range.
- Screening MRI Brain or MRA Head for aneurysms is generally not supported in individuals with coarctation of the aorta repaired before age 3 since there is not an increased risk for intracranial aneurysm in this individual population.

Pediatric Intracranial Arteriovenous Malformations (AVM) (PEDHD-10.2)

- A pertinent evaluation including a detailed history, physical examination with a thorough neurologic examination, and appropriate laboratory studies should be performed prior to considering advanced imaging, unless the individual is undergoing guideline-supported scheduled follow-up imaging evaluation or request is from or in consultation with a neurologist or neurosurgeon who has seen the individual since onset of symptoms.
- Ultrasound Head (CPT® 76506) is the study of choice for evaluation of a suspected vein of Galen malformation in the neonate. Once confirmed, MRI or conventional angiography are required to precisely identify the feeding arteries and draining vein, especially if embolization is planned.
- MRA or CTA are indicated for diagnosis of low flow malformations.
- MRI Brain without and with contrast (CPT® 70553) is the initial study of choice for evaluation of suspected AVM after the neonate period.
 - ◆ MRA, CTA, or CT are generally not indicated prior to completion of initial MRI.
- MRI Brain without contrast (CPT® 70551) or without and with contrast (CPT® 70553), and MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546) or CTA Head (CPT® 70496) are indicated in the following circumstances for individuals with known AVM:
 - ◆ Repeat advanced imaging with MRI Brain without and with contrast (CPT® 70553) or without contrast (CPT® 70551), AND/OR MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546) or CTA Head (CPT® 70496) when requested by a specialist or any provider in consultation with a specialist

- Head imaging for AVM screening is indicated for the following conditions:
 - ◆ Hereditary Hemorrhagic Telangiectasia (Osler-Weber-Rendu Syndrome).
 - MRI Brain without and with contrast (CPT® 70553) is indicated as an initial screening study for infants born to a parent with known HHT.
 - MRI Brain without and with contrast (CPT® 70553) at the time of diagnosis, and a single repeat study after the age of 20.
 - Ongoing surveillance imaging is not indicated for individuals without new or worsening symptoms.
 - Repeat MRI alone or with MRA or CTA (as above) is indicated for clinical signs or symptoms concerning for progression in an individual with a known AVM.
 - CTA (as above) is indicated for clinical signs or symptoms concerning for progression in an individual with a clipped AVM.
 - ◆ Capillary Malformation-Arteriovenous Malformation (CM-AVM)
 - Caused by *RASA1* mutations.
 - MRI Brain without and with contrast (CPT® 70553) at the time of diagnosis.
 - Ongoing surveillance imaging is not indicated for individuals without new or worsening symptoms.
 - Repeat MRI alone or with MRA or CTA (as above) is indicated for clinical signs or symptoms concerning for progression in an individual with a known AVM.
 - See **Vascular Anomalies (PEDPVD-2)** in the Pediatric Peripheral Vascular Disease Imaging Guidelines.
 - ◆ Sturge-Weber Syndrome:
 - MRI Brain without and with contrast (CPT® 70553) and MRI Face/Neck (CPT® 70543) at the time of diagnosis.
 - Ongoing surveillance imaging is not indicated for individuals without new or worsening symptoms.
 - Repeat MRI alone or with MRA or CTA (as above) is indicated for clinical signs or symptoms concerning for progression in an individual with a known AVM.
 - ◆ Cerebral Cavernous Malformations:
 - Also known as cavernomas, cavernous angiomas, or cryptic vascular malformations.
 - MRI Brain without and with contrast (CPT® 70553) and MRI Cervical (CPT® 72156) and Thoracic (CPT® 72157) Spine without and with contrast at the time of diagnosis.
 - Ongoing surveillance imaging is not indicated for individuals without new or worsening symptoms.
 - Repeat MRI alone or with MRA or CTA (as above) is indicated for clinical signs or symptoms concerning for progression in an individual with a known AVM.

Background and Supporting Information

- Most intracranial AVMs are congenital, vary widely in their location and type, and are discovered at birth due to associated clinical findings or incidentally later in life. Certain hereditary conditions are associated with an increased risk for AVM development.
- Vascular malformations include arteriovenous, venous, cavernous, and capillary malformations. The vein of Galen malformation is the most common arteriovenous malformation, presenting in neonates with signs of high output congestive heart failure or later in infancy of childhood with signs of hydrocephalus. Low flow venous, cavernous, and capillary malformations may be asymptomatic and discovered incidentally or they may present in childhood with seizures or neurologic findings secondary to intracranial hemorrhage.

References

1. Hetts SW, Meyers PM, Halbach VD, Barkovich AJ. Anomalies of cerebral vasculature: diagnostic and endovascular considerations. In: Barkovich AJ, Raybaud C eds. *Pediatric Neuroimaging*, 6th ed. Philadelphia PA. Wolters Kluwer. 2019; 1177-1241.
2. Barkovich AJ, Raybaud CA. Congenital malformations of the brain and skull. In: Barkovich AJ, Raybaud C, eds. *Pediatric Neuroimaging*, 6th ed. Philadelphia PA. Wolters Kluwer. 2019; 405-632
3. Montaser A, Smith ER. Intracranial Vascular Abnormalities in Children. *Pediatr Clin North Am*. 2021;68(4):825-843. doi:10.1016/j.pcl.2021.04.010
4. Beez T, Steiger H-J, and Hnggi D. Evolution of management of intracranial aneurysms in children: a systematic review of the modern literature. *J Child Neurol*. 2016; 31 (6): 773-783.
5. Alvarez H, and Castillo M. Genetic markers and their influence on cerebrovascular malformations. *Neuroimag Clin N Am*. 2015 Feb; 25 (1): 69-82.
6. Danti A, Spinardi L, Brighenti M, et al. Frequency of intracranial aneurysms determined by magnetic resonance angiography in children (mean age 16) having operative or endovascular treatment of coarctation of the aorta (mean age 13). *Am J Cardiol*. 2015 epub 2015 Aug; 116 (4):630-633.
7. McDonald J, and Pyritz RE. Hereditary hemorrhagic telangiectasia. *GeneReviews™*, [Internet] eds. Pagon RA, Adam MP, Bird TD et al. version February 2, 2017.
8. Comi A and Pevsner J. Sturge-Weber syndrome. *OrphanetJ Rare Dis*. updated March 2014. <https://rarediseases.org/rare-diseases/sturge-weber-syndrome/>.
9. Morrison L, and Akers A. Cerebral cavernous malformation, familial. *GeneReviews™* [Internet] eds. Pagon RA, Adam MP, Bird TD et al. version August 4, 2016.
10. Linscott LL, Leach JL, Jones BV, et al. Developmental venous anomalies of the brain in children—imaging spectrum and update. *Pediatr Radiol*. 2016 Mar; 46 (3): 394-406.
11. Ghali MGZ, Srinivasan VM, Cherian J, et al. Pediatric Intracranial Aneurysms: Considerations and Recommendations for Follow-Up Imaging. *World Neurosurgery*. 2018;109:418-431.
12. Bernstein, Daniel. Diseases of the Blood Vessels (Aneurysms and Fistulas). *Nelson Textbook of Pediatrics*, Chapter 471. eds eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21st edition. 2020, pp 2487-2490.
13. Derdeyn CP, Zipfel GJ, Albuquerque FC, et al. Management of Brain Arteriovenous Malformations: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke*. 2017;48(8). doi:10.1161/str.000000000000134.
14. Martin KL. Vascular Disorders. *Nelson Textbook of Pediatrics*, Chapter 669. eds eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21stth edition. 2020, pp 3461-3469.
15. Bober MB, Jackson AP. Microcephalic Osteodysplastic Primordial Dwarfism, Type II: a Clinical Review. *Current Osteoporosis Reports*. 2017;15(2):61-69. doi:10.1007/s11914-017-0348-1.
16. Bober MB, Jackson AP. Erratum to: Microcephalic Osteodysplastic Primordial Dwarfism, Type II: a Clinical Review. *Curr Osteoporos Rep*. 2017;15(4):399. doi:10.1007/s11914-017-0389-5
17. Madhuban A, van den Heuvel F, van Stuijvenberg M. Vein of Galen Aneurysmal Malformation in Neonates Presenting With Congestive Heart Failure. *Child Neurol Open*. 2016;3:2329048X15624704. Published 2016 Apr 4. doi:10.1177/2329048X15624704
18. Siegel MJ. Brain. In: *pediatric sonography*. 5th ed. Philadelphia. Wolters Kluwer. 2018 40-111.

Syncope (PEDHD-11)

Syncope (PEDHD-11.1)

- Syncope in children is almost always neurocardiogenic (vasovagal) in nature. Intracranial mass lesions do not cause isolated syncope. Syncope and seizure activity can often be challenging to distinguish for unwitnessed syncope.
- Advanced imaging of the brain is not indicated for individuals with isolated syncope without focal neurologic findings. See **Syncope (PEDCD-5)** in the Pediatric Cardiac Imaging Guidelines and **Epilepsy and Other Seizure Disorders (PEDHD-6)** for additional imaging considerations.
- There is no role for advanced neuroimaging for Postural Tachycardia Syndrome (POTS).

References

1. Friedman KG, and Alexander ME. Chest pain and syncope in children: a practical approach to the diagnosis of cardiac disease. *J Pediatr*. 2013 Sep; 163 (3):896-901.
2. Cannon B, and Wackel P. Syncope. *Pediatr Rev*. 2016 Apr; 37 (4):159-168.
3. Fant C, Cohen A. Syncope In Pediatric Patients: A Practical Approach To Differential Diagnosis And Management In The Emergency Department. *Pediatric emergency medicine practice*. 2017 Apr;14(4):1-28.
4. Dala AS and Van Hare GF. Syncope. *Nelson Textbook of Pediatrics*, Chapter 87. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21stth edition. 2020, pp 569-571.

Pediatric Stroke (PEDHD-12)	
General Considerations (PEDHD-12.1)	50
Pediatric Stroke Initial Imaging (PEDHD-12.2)	50
Pediatric Stroke Subsequent Imaging (PEDHD-12.3)	50
Moyamoya Disease (PEDHD-12.4)	51
Sickle Cell Disease (PEDHD-12.5)	51
CNS Vasculitis and Stroke (PEDHD-12.6)	52
COVID-19 and Multisystem Inflammatory Syndrome in Children (MIS-C) (PEDHD-12.7)	53

General Considerations (PEDHD-12.1)

- Imaging indications are the same for neonates as for older children.

Pediatric Stroke Initial Imaging (PEDHD-12.2)

- Individuals may not present with typical stroke findings. MRI Brain without contrast (CPT® 70551) or MRI Brain without and with contrast (CPT® 70553) is appropriate in the presence of neurological signs and/or symptoms with concern for stroke.⁴
- ANY of the following studies are indicated for evaluation:
 - ◆ CT Head without contrast (CPT® 70450) or MRI Brain without contrast (CPT® 70551)
 - ◆ MRA Head (CPT® 70544) or CTA Head (CPT® 70496)
 - ◆ For suspected carotid dissection CTA Neck (CPT® 70498) or MRA Neck (CPT® 70547, CPT® 70548 or CPT® 70549)
 - ◆ Note: Both MRA or CTA Head and Neck are needed to visualize the posterior vertebrobasilar circulation for evaluation of the vertebrobasilar stroke/TIA (vertigo associated with diplopia, dysarthria, bifacial numbness or ataxia) or concern for arterial dissection (risks may include premature stroke [under age 50], head or neck trauma, fibromuscular dysplasia, Ehlers-Danlos syndrome, and chiropractic neck manipulation)
- In individuals with COVID-19, See **COVID-19 and Multisystem Inflammatory Syndrome in Children (MIS-C) (PEDHD-12.7)**

Pediatric Stroke Subsequent Imaging (PEDHD-12.3)

- MRI Brain without contrast (CPT® 70551) or without and with contrast (CPT® 70553) is indicated for any new or worsening neurological findings or seizure activity.
- Repeat imaging for follow up and resolution of stroke or hemorrhage as determined by a neurology specialist or any provider in consultation with a neurology specialist.
 - ◆ MRI Brain without contrast (CPT® 70551) or without and with contrast (CPT® 70553)
 - ◆ MRA Head/MRV Head (CPT® 70544, CPT® 70545 or CPT® 70546) or CTA Head/CTV Head (CPT® 70496) for follow-up of known cerebral artery stenosis or thrombosis^{4,7}
 - ◆ Other surveillance imaging indications after stroke are listed in the disease-specific sections.

Background and Supporting Information

- CT and MR Venography (CTV and MRV) are reported with the same codes as the CTA/MRA counterpart (there is no specific code for CT/MR venography):
 - ◆ If arterial and venous CT or MR studies are both performed in the same session, only **one** CPT® code is used to report both procedures
 - ◆ If an arterial CTA or MRA study has been performed and subsequently a repeat study is needed to evaluate the venous anatomy, then this study is supported
 - ◆ If a venous CTV or MRV study has been performed and subsequently a repeat study is needed to evaluate the arterial anatomy, then this study is supported
 - ◆ MRA without and with contrast with venous sinus thrombosis to differentiate total from subtotal occlusion

Moyamoya Disease (PEDHD-12.4)

Initial imaging:

- MRI Brain without contrast (CPT® 70551) or without and with contrast (CPT® 70553) MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546) and MRA Neck (CPT® 70547, CPT® 70548, or CPT® 70549) are indicated for all individuals. CTA Head and Neck (CPT® 70496 and CPT® 70498) can be appropriate if MRI is contraindicated or not readily available.

Repeat imaging:

- MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546) every 12 months. CTA Head (CPT® 70496) can be appropriate if MRI is contraindicated or not readily available
- MRI Brain without contrast (CPT® 70551) every 12 months
- Radiopharmaceutical Localization Imaging SPECT (CPT® 78803) with vasodilating agent acetazolamide (Diamox) challenge can be appropriate when surgery or other vascular intervention is being considered.
- CT or MRI Perfusion See **General Guidelines-Other Imaging Situations (PEDHD-1.4)**

Sickle Cell Disease (PEDHD-12.5)

- The following imaging is indicated for all sickle cell individuals with a severe phenotype (Hgb SS or Hgb S β^0):
 - ◆ Transcranial Doppler (TCD) Ultrasound (CPT® 93886 or CPT® 93888) annually for all individuals age 2 to 16. TCD is used to screen for overt and silent infarctions and monitor response to transfusion therapy.
 - A short interval repeat study is indicated for individuals with conditional (170-199 cm/sec) flow results, or with individuals undergoing transfusion therapy.
 - MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546) or CTA Head (CPT® 70496) is appropriate with 2 non-imaging TCD measurements of ≥ 200 cm/sec or a single measurement of >220 cm/sec or 2 assessment TCD measurements ≥ 185 cm/sec or a single measurement >205 cm/sec.
 - MRI Brain without contrast (CPT® 70551) or without and with contrast (CPT® 70553) and/or MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546) is/are indicated in individuals with persistent abnormal TCD velocities
 - ◆ TCD for children aged 17 years old may be appropriate on a case by case basis. See **Stroke/TIA (HD-21.1)** in the Head Imaging Guidelines
 - ◆ After 17 years old, for patients with a history of abnormal TCDs, TCDs may be repeated every 3 months.
 - ◆ TCD is not indicated for individuals with other phenotypes (Hgb SC, Hgb S β^+).
 - ◆ A 1-time MRI Brain (CPT® 70551 or CPT® 70553) screening without sedation to detect silent cerebral infarcts in early-school-age children, when MRI can commonly be performed without sedation. A second screening MRI can be considered if new symptoms or cognitive impairment occurs or a change in academic performance is noted.

- ◆ After an infarct-like lesion is identified, MRI Brain (CPT® 70551 or CPT® 70553) surveillance every 12-24 months to assess for cerebral infarct progression
- ◆ MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546) for any new findings of MRI Brain abnormalities.¹⁹
- ◆ Otherwise screening of asymptomatic sickle cell individuals with MRI or MRA is no longer recommended.
- ◆ MRI Brain without contrast or MRI Brain without and with contrast (CPT® 70551 or CPT® 70553) and MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546) is appropriate prior to any change in therapy.²⁰⁻²⁵

Background and Supporting Information

- Individuals with sickle cell disease are at significantly increased risk for stroke and silent infarction, beginning at a very young age. Recent advances allow physicians to identify individuals at high risk for stroke and begin a primary stroke prevention program.
- Identification of silent cerebral infarction is important because treatment with prophylactic red cell transfusions to maintain hemoglobin S levels at <30% of total hemoglobin may reduce recurrent stroke and extent of neurologic damage.

CNS Vasculitis and Stroke (PEDHD-12.6)

- MRI Brain without and with contrast is the recommended initial study for all individuals with vasculitis and suspected CNS involvement, whether primary or secondary.
 - ◆ A normal MRI Brain almost always completely excludes intracranial vasculitis.
 - ◆ MRA Head (CPT® 70544, CPT® 70545, or CPT® 70546) is indicated for inconclusive MRI findings suggesting medium or large vessel vasculitis.
 - ◆ Individuals with aggressive disease being treated with systemic therapy can have imaging for treatment response every 3 months during active treatment.
 - ◆ Annual surveillance imaging is appropriate to detect progressive vascular damage that may require intervention.

COVID-19 and Multisystem Inflammatory Syndrome in Children (MIS-C) (PEDHD-12.7)

- MRI Brain without contrast (CPT® 70551) or MRI Brain without and with contrast (CPT® 70553) is appropriate in the presence of neurological signs and/or symptoms, including headache, after COVID -19 infection
- COVID-19 infections in children are generally mild in comparison to that of adults, however a post viral syndrome in children has become increasingly noted. Multisystem Inflammatory Syndrome in Children (MIS-C) can cause an inflammatory vasculopathy, prothombotic state and/or post viral myocarditis in children who have had a COVID-19 infection caused by SARS-CoV-2. The child may have had minor symptoms or been asymptomatic at the time of COVID-19 infection but the virus can trigger endothelial injury and activation of the IL-1 pathway similar to that in Kawasaki disease and acute rheumatic fever.
 - ◆ Symptoms of MIS-C may include some or all of the following:
 - Headache, irritability
 - Mucocutaneous changes similar to Kawasaki disease (i.e. strawberry tongue, red cracked lips, rash of hands and/or feet)
 - Polymorphous or vasculitic rash
 - Non-exudative conjunctivitis
 - Tachycardia, hypotension
 - Cough, shortness of breath
 - Abdominal pain, vomiting, diarrhea
 - Lymphadenopathy, joint pain, sore throat
- MRI Brain (CPT® 70553 or CPT® 70551), MRA Head (CPT® 70544, CPT® 70545 or CPT® 70546) and MRA Neck (CPT® 70547 or CPT® 70548 or CPT® 70549) is appropriate in children presenting with any of these symptoms after known or presumed COVID-19 infection. MRA is the preferred study in children however, CTA Head (CPT® 70496) and/or Neck (CPT® 70498) is appropriate if MRA is contraindicated.
- If concern for CNS infection – See **CNS Infection (PEDHD-29.1)**
- See **PEDCD-12: Multisystem inflammatory syndrome in children (MIS-C)** in the Pediatric Cardiac Imaging Guidelines

References

1. Naula S, Yeshokumar AK and Banwell BL. Central Nervous System Vasculitis. Nelson Textbook of Pediatrics, Chapter 620. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21st edition. 2020, pp 3219-3221.
2. Sultan SM. Stroke in Children. Chapter 144. Louis ED, Mayer SA, Rowland LP (Ed.). Merritt's Neurology. 13th Ed. 2015.
3. Robertson RL, et al. American College of Radiology ACR Appropriateness Criteria® Cerebrovascular Disease—Child. New 2019. 1-23.
4. Ferriero DM, Fullerton HJ, Bernard TJ, et al. Management of Stroke in Neonates and Children: A Scientific Statement From the American Heart Association/American Stroke Association. Stroke. 2019;50(3). doi:10.1161/str.0000000000000183.
5. Mirsky DM, Beslow LA, Amlie-Lefond C, et al. Pathways for Neuroimaging of Childhood Stroke. Pediatric Neurology. 2017;69:11-23. doi:10.1016/j.pediatrneurol.2016.12.004.
6. Soliman M, Laxer R, Manson D, et al. Imaging of systemic vasculitis in childhood. Pediatr Radiol. 2015 Aug; 45(8):1110-1125.
7. Khalaf A, Iv M, Fullerton H, Wintermark M. Pediatric Stroke Imaging. Pediatric Neurology. 2018;86:5-18. doi:10.1016/j.pediatrneurol.2018.05.008.
8. Choudri A, Zaza A, Auschwitz T, Mossa-Basha M. Noninvasive vascular imaging of moyamoya: Diagnosis, followup, and surgical planning. Journal of Pediatric Neuroradiology 3 (2014) 13–20. doi:10.3233/PNR-14082
9. Dlamini Nomazulu and deVeber GA. Pediatric Stroke. Nelson Textbook of Pediatrics, Chapter 471. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21st edition. 2020, pp 3209-3212.
10. Smith-Whitley K. Sickle Cell Disease. Nelson Textbook of Pediatrics, Chapter 489.1. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21st edition. 2020, pp 2541-2550.
11. ACR-ASNR- SPR Practice Parameters for the performance of Computed Tomography (CT) perfusion in neuroradiologic imaging. Revised 2017. Resolution 18. <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/CT-Perfusion.pdf>
12. Debaun MR, Jordan LC, King AA, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Advances. 2020;4(8):1554-1588. doi:10.1182/bloodadvances.2019001142
13. McMurray JC, May JW, Cunningham MW and Jones OY(2020) Multisystem Inflammatory Syndrome in Children (MIS-C), a Post-viral Myocarditis and Systemic Vasculitis—A Critical Review of Its Pathogenesis and Treatment. Front. Pediatr. 8:626182. doi: 10.3389/fped.2020.626182
14. Jiang Li, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis 2020; 20: e276–88
15. Information for Healthcare Providers about Multisystem Inflammatory Syndrome in Children (MIS-C) <https://www.cdc.gov/mis-c/hcp/>
16. Panda PK, Sharawat IK, Panda P, Natarajan V, Bhakat R, Dawman L. Neurological Complications of SARS-CoV-2 Infection in Children: A Systematic Review and Meta-Analysis [published online ahead of print, 2020 Sep 10]. J Trop Pediatr. 2020;fmaa070. doi:10.1093/tropej/fmaa070
17. Lin JE, Asfour A, Sewell TB, et al. Neurological issues in children with COVID-19. Neurosci Lett. 2021;743:135567. doi:10.1016/j.neulet.2020.135567
18. Bernaudin F, Verlhac S, Arnaud C, et al. Long-term treatment follow-up of children with sickle cell disease monitored with abnormal transcranial Doppler velocities. Blood. 2016;127(14):1814-1822. doi:10.1182/blood-2015-10-675231
19. DeBaun MR, Jordan LC, King AA, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv. 2020;4(8):1554-1588. doi:10.1182/bloodadvances.2019001142.
20. Nickel RS, Kamani NR. Ethical Challenges in Hematopoietic Cell Transplantation for Sickle Cell Disease. Biol Blood Marrow Transplant. 2018;24(2):219-227. doi:10.1016/j.bbmt.2017.08.034
21. Krishnamurti L. Hematopoietic Cell Transplantation for Sickle Cell Disease. Front Pediatr. 2021;8:551170. Published 2021 Jan 5. doi:10.3389/fped.2020.551170
22. King AA, McKinsty RC, Wu J, et al. Functional and Radiologic Assessment of the Brain after Reduced-Intensity Unrelated Donor Transplantation for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network Study 0601. Biol Blood Marrow Transplant. 2019;25(5):e174-e178. doi:10.106/j.bbmt.2019.01.008
23. Kanter J, Liem RI, Bernaudin F, et al. American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation. Blood Adv. 2021;5(18):3668-3689. doi:10.1182/bloodadvances.2021004394C
24. Jordan LC, Kassim AA, Wilkerson KL, Lee CA, Waddle SL, Donahue MJ. Using novel magnetic resonance imaging methods to predict stroke risk in individuals with sickle cell anemia. Hematol Oncol Stem Cell Ther. 2020;13(2):76-84. doi:10.1016/j.hemonc.2019.12.009
25. Hirtz D, Kirkham FJ. Sickle Cell Disease and Stroke. Pediatr Neurol. 2019;95:34-41. doi:10.1016/j.pediatrneurol.2019.02.018.

Benign Brain Lesions (PEDHD-13)

Arachnoid Cysts (PEDHD-13.1)	56
Pineal/Colloid Cysts (PEDHD-13.2)	56
Acoustic Neuromas (PEDHD-13.3)	56

Arachnoid Cysts (PEDHD-13.1)

- Arachnoid cysts arise in the middle or posterior fossa, and the majority of lesions are discovered incidentally and do not require surgical intervention.
- MRI Brain without contrast (CPT® 70551) or without and with contrast (CPT® 70553) is indicated for initial evaluation of arachnoid cysts if not already completed.
- Repeat MRI Brain is not indicated for most individuals with arachnoid cysts, but is appropriate for the following:
 - ◆ Annual MRI Brain without contrast (CPT® 70551) or without and with contrast (CPT® 70553) until age 4 if diagnosed at a younger age.
 - ◆ New or worsening headache or focal neurologic deficits suggesting progression of cyst.
 - ◆ Preoperative planning.
 - ◆ When requested by a specialist or any provider in consultation with a specialist

Pineal/Colloid Cysts (PEDHD-13.2)

- Pineal cysts are generally discovered incidentally and do not require surgical intervention.
- MRI Brain without contrast (CPT® 70551) or without and with contrast (CPT® 70553) is indicated for initial evaluation of pineal cysts if not already completed.
- Repeat MRI Brain is not indicated for most individuals with pineal cysts, but MRI Brain without contrast (CPT® 70551) or without and with contrast (CPT® 70553) is appropriate for the following:
 - ◆ New or worsening headache or focal neurologic deficits suggesting progression of cyst.
 - ◆ Preoperative planning.
- Repeat MRI Brain without contrast (CPT® 70551) or without and with contrast (CPT® 70553) is appropriate for colloid cysts for the following:
 - ◆ In the presence of symptoms including syncope
 - ◆ Evaluation of CSF flow (CPT® 70551)
 - ◆ When requested by a specialist or any provider in consultation with a specialist

Acoustic Neuromas (PEDHD-13.3)

- See **Neurofibromatosis 2 (PEDPN-2.2)** in the Pediatric Peripheral Nerve Disorders Imaging Guidelines.

References

1. Hervey-Jumper SL, Cohen-Gadol AA, and Maher CO. Neurosurgical management of congenital malformations of the brain. *Neuroimag Clin N Am*. 2011 Aug; 21 (3): 705-717.
2. Jussila M-P, Olsén P, Salokorpi N, Suo-Palosaari M. Follow-up of pineal cysts in children: is it necessary? *Neuroradiology*. 2017;59(12):1265-1273.
3. Raybaud C, Patay Z, Barkovich. Intracranial, orbital and neck masses in children. In: Barkovich AJ, Raybaud C, eds. *Pediatric Neuroimaging*, 6th ed. Philadelphia PA. Wolters Kluwer. 2019; 703-906.
4. Bulas D. Prenatal Imaging. *Caffey's Pediatric Diagnostic Imaging*, Chapter 621. Coley BR, et al. 13th edition. 2019, pp 245-250.
5. Koral Korgun. Neoplasia. *Caffey's Pediatric Diagnostic Imaging*, Chapter 12. Coley BR, et al. 13th edition. 2019, pp 93-96.
6. Lagman C, Rai K, Chung LK, et al. Fatal Colloid Cysts: A Systematic Review. *World Neurosurgery*. 2017;107:409-415. doi:10.1016/j.wneu.2017.07.183.
7. Goldbrunner R, Weller M, Regis J, et al. EANO guideline on the diagnosis and treatment of vestibular schwannoma. *Neuro-Oncology*. 2019;22(1):31-45. doi:10.1093/neuonc/noz153.
8. Muhlestein WE, Maher CO. Incidental Intracranial Cysts in Children. *Pediatr Clin North Am*. 2021;68(4):775-782. doi:10.1016/j.pcl.2021.04.005

Pediatric Demyelinating Diseases (PEDHD-14)	
General Considerations (PEDHD-14.1)	58
Multiple Sclerosis (MS) (PEDHD-14.2)	58
Acute Disseminated Encephalomyelitis (ADEM) and Other Pediatric Demyelinating Disorders (PEDHD-14.3)	59
Transverse Myelitis (PEDHD-14.4)	60

General Considerations (PEDHD-14.1)

- MRI Brain without and with contrast (CPT® 70553) is the preferred imaging study for evaluation of pediatric demyelinating disease.
 - ◆ MRI Spinal Cord without and with contrast (CPT® 72156 and CPT® 72157) is also indicated for evaluation of pediatric demyelinating disease.
 - ◆ MRI Lumbar Spine without and with contrast (CPT® 72158) is not indicated unless the individual has a tethered cord or other anatomic abnormality causing caudal displacement of the filum terminalis.
- CT imaging is generally not indicated in the evaluation of demyelinating disease.
- Metabolic (FDG) PET Brain (CPT® 78608) and MR Spectroscopy (CPT® 76390) are considered investigational for evaluation of pediatric demyelinating diseases.
- See **Neurometabolic and Neurogenetic Disorders (PEDHD-19.4)**

Multiple Sclerosis (MS) (PEDHD-14.2)

- MRI Brain (CPT® 70553) and Spinal Cord (CPT® 72156 and CPT® 72157) without and with contrast is indicated for initial diagnosis in individuals with clinical signs and/or symptoms suggestive of MS.
 - ◆ MRI Brain (CPT® 70551) and Spinal Cord (CPT® 72141 and CPT® 72146) without contrast is appropriate if there is a contraindication to gadolinium administration.
- MRI Brain without contrast (CPT® 70551), which is preferred, OR MRI Brain without and with contrast (CPT® 70553) is indicated every 6 months for disease monitoring whether or not receiving treatment.¹⁹
 - ◆ MRI Spinal Cord (CPT® 72156 and CPT® 72157) without and with contrast OR Spinal Cord (CPT® 72141 and CPT® 72146) without contrast is (are) indicated every 12 months or for new signs or symptoms.¹⁹
 - ◆ MRI Orbit without and with contrast (CPT® 70543) may be considered if opticneuritis is suspected, in addition to the above scenario
 - ◆ Symptoms suggestive of Progressive Multifocal Leukoencephalopathy (PML) during Tysabri therapy (or other medications with similar risk).
 - Screening for individuals on natalizumab (Tysabri) or other drugs with risk of PML (Progressive Multifocal Leukoencephalopathy)
 - MRI Brain every 6 months while on treatment
 - MRI Brain every 3-6 months for high risk individuals positive for serum JC virus antibody and >18 months natalizumab exposure
- If a non-contrast study shows incidental evidence of possible demyelinating disease, repeat with MRI Brain with contrast (CPT® 70552) is appropriate within 2 weeks of previous non-contrast study as the presence of enhancing lesions may be helpful in confirming the diagnosis. If non-contrast study was performed more than 2 weeks prior to the performance of the repeat imaging, an MRI Brain with and without contrast (CPT® 70553) is appropriate

Background and Supporting Information

- Multiple sclerosis is less common in children. About 4% of MS cases are diagnosed before age 18, and only ~0.7% of all MS cases begin before age 10.
- Ataxia, optic neuritis, diplopia, and transverse myelitis are common presentations. MS can present as an acute encephalitis-like illness, especially in childhood.
- Among children with suspected demyelinating diseases, the principal differential diagnosis is often between MS and acute disseminated encephalomyelitis.
- Medications with similar risks of PML as Tysabri include: Dimethyl fumarate (Tecfidera), Fingolimod (Gilenya), Ocrelizumab (Ocrevus), Mavenclad (cladribine), Vumerity (diroximel fumarate), Soliris (eculizumab), Zeposia (ozanimod), Lemtrada (alemtuzumab), Bafiertam (monomethyl fumarate), Rituxan (rituximab).
- 3D imaging in the evaluation of Multiple Sclerosis is not approvable as a separate code as most scanners are capable of 3D acquisitions or other imaging sequences may be done.

Acute Disseminated Encephalomyelitis (ADEM) and Other Pediatric Demyelinating Disorders (PEDHD-14.3)

- MRI Brain (CPT® 70553) and Spinal Cord (CPT® 72156 and CPT® 72157) without and with contrast is indicated for initial diagnosis in individuals with clinical signs and/or symptoms suggestive of ADEM.
 - ◆ MRI Brain (CPT® 70551) and Spinal Cord (CPT® 72141 and CPT® 72146) without contrast can be approved if there is a contraindication to gadolinium.
- MRI Brain (CPT® 70553) and Spinal Cord (CPT® 72156 and CPT® 72157) without and with contrast is indicated every 3 months for 1 year following diagnosis or if ordered out of sequence or beyond one year by a specialist or any provider in consultation with a specialist.
 - ◆ MRI Brain (CPT® 70551) and Spinal Cord (CPT® 72141 and CPT® 72146) without contrast can be approved if there is a contraindication to gadolinium.
 - ◆ Most individuals will have complete clinical recovery by 12 months, while stable MRI abnormalities (gliosis) may persist. These findings do not require additional imaging unless the individual develops new neurologic symptoms. Prolonged symptoms or return of symptoms may represent a different demyelinating disorder
- There are other pediatric demyelinating disorders that are less common but have clinical overlap with multiple sclerosis and ADEM such as (but not limited to):
 - ◆ Neuromyelitis optica (NMO) spectrum disorders (See **Neuromyelitis Optica and NMO Spectrum Disorders (HD 16.2)**)
 - ◆ Anti-MOG syndromes (anti-myelin oligodendrocyte glycoprotein) (See **Anti-MOG Syndromes (HD 16.3)**)
 - ◆ Demyelination secondary to infectious or inflammatory disorders (e.g. transverse myelitis) (See **General Guidelines – Other Imaging Situations (HD 1.7)**)

- These conditions may require a different treatment regimen than multiple sclerosis and may require repeat imaging to monitor treatment response as the diagnosis becomes more clear. Repeat imaging with MRI Brain and/or MRI Cervical Spine and MRI Thoracic Spine as requested by neurology or infectious disease may be approved.
- See **Neurometabolic and Neurogenetic Disorders (PEDHD-19.4)**

Background and Supporting Information

- ADEM has an acute onset, and is more common among younger children than MS, but the signs and symptoms overlap significantly, and distinguishing between MS and ADEM can be challenging based on clinical examination alone.

Transverse Myelitis (PEDHD-14.4)

- Transverse myelitis is an inflammatory disorder of the spine and can be:
 - ◆ Idiopathic
 - ◆ Associated with autoimmune central nervous system inflammatory disease
 - First event of multiple sclerosis (MS)
 - Neuromyelitis optica (NMO)
 - MOG (Myelin Oligodendrocyte Glycoprotein) antibody disorder
 - ◆ Associated with connective tissue autoimmune diseases
 - Systemic Lupus Erythematosus (SLE)
 - Systemic Sclerosis
 - Rheumatoid Arthritis (RA)
 - Sjogren's Syndrome (SS)
 - Neuro-Sarcoidosis (NS)
 - ◆ Post-infectious or post-vaccine neurological syndrome

See **Multiple Sclerosis (MS) and Related Conditions (HD-16)**

References

1. Hemingway C. Demyelinating disorders of the central nervous system. Nelson Textbook of Pediatrics, Chapter 618. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21st edition. 2020, pp 3197-3209.
2. Weygandt M, Hummel H-M, Schregel K, et al. MRI-based diagnostic biomarkers for early onset pediatric multiple sclerosis. *NeuroImage: Clinical*. 2015;7:400-408. doi:10.1016/j.nicl.2014.06.015.
3. Tenembaum SN. Pediatric multiple sclerosis. Distinguishing clinical and MR imaging features. *Neuroimag Clin* 2017; 27:229-250.
4. Van Haren K, and Waubant E. Therapeutic advances in pediatric multiple sclerosis. *J Pediatr*. 2013 Sep; 163 (3): 631-637.
5. Ketelslegers IA, Neuteboom RF, Boon M, et al. A comparison of MRI criteria for diagnosing pediatric ADEM and MS. *Neurology*. 2010 Mar; 74 (18): 1412; 1415.
6. Banwell B, Arnold DL, Tillema J-M, et al. MRI in the evaluation of pediatric multiple sclerosis. *Neurology*. 2016;87(9 Supplement 2). doi:10.1212/wnl.0000000000002787.
7. Marin SE, and Callen DJA. The magnetic resonance imaging appearance of monophasic acute disseminated encephalomyelitis: an update post application of the 2007 consensus criteria. *Neuroimag Clin N Am*. 2013 May; 23 (2): 245-266.
8. Neuteboom R, Wilbur C, Pelt DV, Rodriguez M, Yeh A. The Spectrum of Inflammatory Acquired Demyelinating Syndromes in Children. *Seminars in Pediatric Neurology*. 2017;24(3):189-200
9. Ruet A. Update on pediatric-onset multiple sclerosis. *Revue Neurologique*. 2018;174(6):398-407. doi:10.1016/j.neurol.2018.04.003.
10. Troxell RM, Christy A. Atypical Pediatric Demyelinating Diseases of the Central Nervous System. *Current Neurology and Neuroscience Reports*. 2019;19(12). doi:10.1007/s11910-019-1015-y.
11. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *The Lancet Neurology*. 2018;17(2):162-173. doi:10.1016/s1474-4422(17)30470-2.
12. Expert Panel on Neurologic Imaging; Kennedy TA, Corey AS, et al. ACR Appropriateness Criteria® Orbits Vision and Visual Loss. *J Am Coll Radiol*. 2018;15(5S):S116-S131. doi:10.1016/j.jacr.2018.03.023
13. Wingerchuk DM et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. *Neurology*. 2015 Jul 14; 85(2):177-89. doi: 10.1212/WNL.0000000000001729.
14. Major EO. Progressive Multifocal Leukoencephalopathy Lesions and JC Virus. *JAMA Neurology*. 2018;75(7):789. doi:10.1001/jamaneurol.2018.0004.
15. Vukusic S, Rollot F, Casey R, et al. Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France. *JAMA Neurology*. 2020;77(1):94. doi:10.1001/jamaneurol.2019.2670.
16. Rae-Grant A, et al. Practice guideline: Disease-modifying therapies for adults with multiple sclerosis. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
17. Wattjes MP, Barkhof F. Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. *Current Opinion in Neurology*. 2014;27(3):260-270. doi:10.1097/wco.0000000000000099.
18. Barraza G, Deiva K, Husson B, Adamsbaum C. Imaging in pediatric multiple sclerosis. *Clinical Neuroradiology* 2021; 31:61-71.
19. Wattjes MP, Ciccarelli O, Reich DS, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. *The Lancet Neurology*. 2021;20(8):653-670. doi:10.1016/S1474-4422(21)00095-8.

Pituitary Dysfunction (PEDHD-15)	
General Considerations (PEDHD-15.1)	63
Panhypopituitarism (PEDHD-15.2)	63
Isolated Growth Hormone Deficiency (PEDHD-15.3)	64
Diabetes Insipidus (DI) and Other Disorders of Anti-Diuretic Hormone (PEDHD-15.4)	65
Precocious Puberty (PEDHD-15.5)	66
Benign Pituitary Tumors (PEDHD-15.6)	67
Pituitary Malignancies (PEDHD-15.7)	67

General Considerations (PEDHD-15.1)

- The initial step in the evaluation of all potential pituitary masses is a detailed history, recent physical examination, and thorough neurological exam, including evaluation of the visual fields.
- Endocrine laboratory studies should be performed prior to considering initial advanced imaging.
- MRI Brain without and with contrast (CPT® 70553) or MRI Brain without contrast (CPT® 70551) when pituitary imaging is indicated.
 - ◆ Pituitary Gland: one study (either MRI Brain [CPT® 70553] or MRI Orbit, Face, Neck [CPT® 70543]) is adequate to report the imaging of the pituitary. The reporting of two CPT® codes, to image the pituitary, is not indicated
- If a previous MRI Brain was reported to show a possible pituitary tumor with supporting evidence of pituitary disease or is inconclusive, a repeat MRI with dedicated pituitary protocol may be performed. If a prior MRI Brain was without contrast a follow up scan either with contrast (CPT® 70552) or with and without contrast (CPT® 70553) is appropriate
- For association between pituitary dysfunction and optic nerve issues See **Eye Disorders and Visual Loss (HD- 32.1)** in the Head Imaging Guidelines
- For repeat imaging, See **Pituitary (HD-19.1)** in the Head Imaging Guidelines

Panhypopituitarism (PEDHD-15.2)

- Endocrine testing should be performed initially.
- MRI Brain without and with contrast (CPT® 70553) or MRI Brain without contrast (CPT® 70551) with special attention to the pituitary is indicated for newly diagnosed Panhypopituitarism.
- Individuals with a normal pituitary on initial MRI do not need routine follow up imaging.
- Individuals with mass lesions should have follow up imaging according to the guidelines for the specific diagnosis.

Isolated Growth Hormone Deficiency (PEDHD-15.3)

- Clinical features include: height below the normal range (<3rd percentile), subnormal growth velocity or the child's height is below the range expected based on parental height.
- Risk factors include: a history of brain tumor, cranial irradiation or other congenital/organic hypothalamic-pituitary abnormality as well as an incidental finding of a hypothalamic-pituitary abnormality on MRI.
- Endocrine testing should be performed initially.
- MRI Brain without and with contrast (CPT® 70553) or MRI Brain without contrast (CPT® 70551) with special attention to the pituitary is indicated for any of the following:
 - ◆ Both IGF1 and IGFBP3 are below the laboratory reference range for age/sex or Tanner stage.
 - ◆ 2 measurements of growth hormone stimulation with different stimulation agents (glucagon, clonidine, arginine, insulin, levodopa) performed on the same day or separate days produce maximal GH levels <10ng/mL See Background and Supporting Information
- Individuals with a normal pituitary on initial MRI do not need routine follow up imaging.
- Individuals with mass lesions should have follow up imaging according to the guidelines for the specific diagnosis.

Background and Supporting Information

- Growth hormone stimulation testing is limited by poor specificity and requires failure on 2 tests to diagnose growth hormone deficiency.
- Controversy exists as to the cutoff level which differentiates a normal response from a deficient response on provocative testing. Some experts support GH <7 ng/mL however many pediatric endocrinologists consider a peak GH level <10 ng/mL to be indicative of growth hormone deficiency and may identify children with partial GHD.

Diabetes Insipidus (DI) and Other Disorders of Anti-Diuretic Hormone (PEDHD-15.4)

- Laboratory testing should be performed initially. Diabetes insipidus is characterized by serum osmolality >300mOsm/kg and urine osmolality <300 mOsm/kg.
- Central diabetes insipidus (CDI) is caused by diminished synthesis or secretion of vasopressin in the hypothalamus and nephrogenic diabetes insipidus (NDI) is caused by renal resistance to vasopressin.

Central Diabetes Insipidus (DI):

- MRI Brain without and with contrast (CPT® 70553) or MRI Brain without contrast (CPT® 70551) is indicated for newly diagnosed central DI.
- Individuals with a normal pituitary on initial MRI can have repeat MRI Brain without and with contrast (CPT® 70553) every 3-6 months for the first 2 years as germinomas may cause central DI while still too small to detect on imaging.
 - ◆ Serial measurement of β -hCG is also indicated for these individuals, and MRI should be repeated if a significant rise in β -hCG is detected on screening.
- Individuals with mass lesions should have follow up imaging according to the guidelines for the specific diagnosis.

Nephrogenic DI:

- Once this diagnosis is firmly established, further advanced imaging is usually not indicated.

Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH):

- Laboratory studies should be obtained prior to considering advanced imaging—urine osmolality should be high and serum osmolality low.
- MRI Brain without and with contrast (CPT® 70553) or MRI Brain without contrast (CPT® 70551) for initial evaluation of unexplained central (hypothalamic pituitary) SIADH.
- Individuals with a normal pituitary on initial MRI do not need routine follow up imaging.
- Individuals with mass lesions should have follow up imaging according to the guidelines for the specific diagnosis.

Background and Supporting Information

- See **Small Cell Lung Cancer-Suspected/Diagnosis (ONC-7.1)** and **Paraneoplastic Syndromes (ONC-30.3)** in the Oncology Imaging Guidelines.
- Pulmonary diseases including infection (tuberculosis, viral/bacterial pneumonia), acute respiratory infections, mechanical ventilation and others can cause SIADH although the mechanism is unclear. Individuals with lung disease should have chest imaging according to the guidelines for the specific diagnosis.

Precocious Puberty (PEDHD-15.5)

- Endocrine laboratory studies (baseline LH, FSH and either estradiol or testosterone) are used to determine if the etiology of precocious puberty is central (gonadotropin dependent) or peripheral (gonadotropin independent). Estradiol and testosterone levels will often be elevated to a pubertal range.

Central Precocious Puberty (CPP)

- An LH >0.3 U/L on a random blood sample is the most reliable screening test for central precocious puberty. If LH <0.3 U/L and CPP is suspected, a stimulation test with a GnRH analog is the gold standard.
- Neuroimaging should always follow hormonal studies that suggest a central origin of precocious puberty.
- MRI Brain without and with contrast (CPT® 70553, preferred study) or MRI Brain without contrast (CPT® 70551) is indicated for evaluation of any child with documented central precocious puberty.
- MRI is appropriate irrespective of age and gender in individuals with precocious puberty and concurrent CNS symptoms of severe headache, visual changes or seizures.
- Individuals with a normal pituitary on initial MRI do not need routine follow up imaging.
- Individuals with mass lesions should have follow up imaging according to the guidelines for the specific diagnosis. (**Benign Pituitary Tumors (PEDHD-15.6)** and **Pituitary Malignancies (PEDHD-15.7)**)

Peripheral Precocious Puberty

- The differential diagnosis of peripheral precocious puberty (LH suppressed or in the pre-pubertal range with elevated estradiol, testosterone and/or adrenal androgens) is broad and may include ovarian, testicular, adrenal and other sources of excessive hormonal production
- Ultrasound Abdomen (CPT® 76700) in both genders and Ultrasound Pelvis (CPT® 76856) in females and Scrotal ultrasound (CPT 76870) in males depending on the suspected source of hormonal excess for initial imaging
- See **CNS Germinomas and Non-Germinomatous Germ Cell Tumors (PEDONC-4.7)** in the Pediatric Oncology Imaging Guidelines for evaluation of HCG secreting CNS tumors.
- See **Hepatoblastoma (PEDONC-11.2)** in the Pediatric Oncology Imaging Guidelines for evaluation of HCG secreting hepatic tumors.
- See **Pediatric Germ Cell Tumors (PEDONC-10)** in the Pediatric Oncology Imaging Guidelines and **Testicular, Ovarian and Extragonadal Germ Cell Tumors (ONC-20)** in the Oncology Imaging Guidelines for evaluation of Leydig Cell tumors.
- See **Adrenal Cortical Lesions (AB-16.1)** in the Abdomen Imaging Guidelines for evaluation of adrenal virilizing tumors

Background and Supporting Information

- Defined as the appearance of secondary sexual characteristics before age 8 in females and before age 9 in males. The diagnosis is made clinically using Tanner staging and often will include a bone age assessment (hand/wrist radiographs) and/or abdominal and/or pelvic ultrasound (See **Peripheral Precocious Puberty**).

Benign Pituitary Tumors (PEDHD-15.6)

- Benign pituitary tumor indications in pediatric individuals are identical to those for adult individuals. See **Pituitary (HD-19)** in the Head Imaging Guidelines.

Pituitary Malignancies (PEDHD-15.7)

- See **Craniopharyngioma and Other Hypothalamic/Pituitary Region Tumors (PEDONC-4.10)** or **Histiocytic Disorders (PEDONC-18)** in the Pediatric Oncology Imaging Guidelines.

References

1. Expert Panel on Neurologic Imaging; Burns J, Policeni B, et al. ACR Appropriateness Criteria® Neuroendocrine Imaging. J Am Coll Radiol. 2019;16(5S):S161-S173. doi:10.1016/j.jacr.2019.02.017
2. Patterson BC and Felner EI. Hypopituitarism. Nelson Textbook of Pediatrics, Chapter 573. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21st edition. 2020, pp 2887-2889.
3. Breault DT and Majzoub JA. Diabetes Insipidus. Nelson Textbook of Pediatrics, Chapter 573. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21st edition. 2020, pp 2887-2889.
4. Garibaldi LR and Chemaitilly W. Physiology of Puberty, Nelson Textbook of Pediatrics, Chapter 577. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21st edition. 2020, pp 2899-2907.
5. Zaky W, Ater JL and Khatua S. Brain Tumors in Childhood. Nelson Textbook of Pediatrics, Chapter 524. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21st edition. 2020, pp 2666-2678.
6. Kaplowitz P, Bloch C. Evaluation and Referral of Children With Signs of Early Puberty. Pediatrics. 2015;137(1). doi:10.1542/peds.2015-3732.
7. Grimberg A, Divall SA, Polychronakos C, et al. Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency. Hormone Research in Paediatrics. 2016;86(6):361-397. doi:10.1159/000452150
8. Thompson CJ et al. Posterior Pituitary. Textbook of Endocrinology. Chapter 10, eds. Melmed S, et al, 14th edition. 2019. pp 303-330.
9. Cooke DW et al. Normal and Aberrant Growth in Children. Textbook of Endocrinology. Chapter 25, eds. Melmed S, et al, 14th edition. 2019. pp 937-1022.
10. Styne DM et al. Physiology and Disorders of Puberty. Textbook of Endocrinology. Chapter 26, eds. Melmed S, et al, 14th edition. 2019. pp 1023-1164.
11. IGFB3 - Clinical: Insulin-Like Growth Factor-Binding Protein 3, Serum. www.mayocliniclabs.com. <https://www.mayocliniclabs.com/test-catalog/Clinical+and+Interpretive/83300>.
12. IGFMS - Clinical: Insulin-Like Growth Factor-1, LC-MS, Serum. www.mayocliniclabs.com. <https://www.mayocliniclabs.com/test-catalog/Clinical+and+Interpretive/62750>

Pediatric Ear Disorders (PEDHD-16)	
Hearing Loss (PEDHD-16.1)	69
Ear Pain (PEDHD-16.2)	70
Cholesteatoma (PEDHD-16.3)	70
Vertigo (PEDHD-16.4)	71
Tinnitus (PEDHD-16.5)	71

Hearing Loss (PEDHD-16.1)

- A pertinent evaluation including a detailed history, physical examination (including otoscopic examination), and age-appropriate audiology testing should be performed on any child with known or suspected hearing loss prior to considering advanced imaging. The selection of imaging testing will depend on the age of the child and type of hearing loss.
- CT Temporal Bone without contrast (CPT® 70480) is indicated for the following:
 - ◆ Conductive hearing loss of any cause.
 - ◆ Preoperative planning for resection of mass lesion or cochlear implant placement.
 - ◆ Sensorineural hearing loss in individuals who cannot safely undergo MRI.
 - ◆ Mixed conductive and sensorineural hearing loss.
 - ◆ Congenital hearing loss.
 - ◆ Total deafness.
- MRI Brain without and with contrast (CPT® 70553) with attention to internal auditory canals (included in CPT® 70553 and does not require a separate CPT code) is indicated for the following:
 - ◆ Conductive hearing loss secondary to known or suspected mass lesion.
 - ◆ Preoperative planning for resection of mass lesion or cochlear implant placement.
 - ◆ Sensorineural hearing loss of any cause.
 - ◆ Mixed conductive and sensorineural hearing loss.
 - ◆ Congenital hearing loss.
 - ◆ Total deafness.
 - ◆ Hearing loss associated with tinnitus See **Tinnitus (PEDHD-16.5)**
- Both modalities (CT and MRI) may be approved simultaneously for evaluation and surgical planning if ordered by or in consultation with an ENT or Neurosurgical specialist
- Limited MRI Brain with attention to internal auditory canals (CPT® 70540, CPT® 70542, or CPT® 70543) can be approved when requested by the provider in place of a complete MRI Brain. Note: Limited MRI codes should not be used in addition to MRI Brain codes; IAC views are performed as additional sequences as part of the brain study. (See **General Guidelines – Anatomic Issues (HD-1.1)** in the Head Imaging Guidelines)

Ear Pain (PEDHD-16.2)

- A pertinent evaluation including a detailed history, physical examination (including otoscopic examination), should be performed on any child with ear pain prior to considering advanced imaging. Common causes of ear pain include external and middle ear infections, dental problems, sinus infection, mastoid infection, neck problems, tonsillitis, and pharyngitis.
- Advanced imaging is not indicated in the overwhelming majority of pediatric individuals with ear pain.
- CT Temporal Bone without contrast (CPT® 70480) or without and with contrast (CPT® 70482), OR, MRI Brain without and with contrast with attention to internal auditory canals (CPT® 70553), OR MRI Orbits/Face/Neck without and with contrast (CPT® 70543) is indicated for the following:
 - ◆ Persistent ear pain without obvious cause.
 - ◆ Clinical suspicion for complicated or invasive infection such as mastoiditis.
 - ◆ Clinical suspicion of mass lesion causing ear pain.
 - ◆ Significant trauma with concern for hematoma formation.
 - ◆ Preoperative planning.

Cholesteatoma (PEDHD-16.3)

- CT Temporal Bone without contrast (CPT® 70480) or without and with contrast (CPT® 70482), OR MRI Brain without and with contrast with attention to internal auditory canals (CPT® 70553), OR MRI Orbits/Face/Neck without and with contrast (CPT® 70543) is indicated for preoperative evaluation in cholesteatoma individuals.
- CT Temporal Bone without contrast (CPT® 70480) or without and with contrast (CPT® 70482), OR MRI Brain without and with contrast with attention to internal auditory canals (CPT® 70553), OR MRI Orbits/Face/Neck without and with contrast (CPT® 70543) is indicated one time post-operatively to exclude residual or regrown cholesteatoma to avoid the need for a second-look surgery.

Background and Supporting Information

- Cholesteatomas are expansive cysts of the middle ear filled with cellular debris. They can be congenital or arise from recurrent middle ear infections or trauma to the tympanic membrane. Hearing loss is usually conductive, although if the lesion is large enough combined conductive and sensorineural hearing loss may be present. Otoscopic exam findings and symptoms may include painless drainage from the ear or chronic/recurrent ear infections.

Vertigo (PEDHD-16.4)

- A pertinent evaluation including a detailed history, physical examination (including otoscopic examination), should be performed on any child with vertigo prior to considering advanced imaging.
- If physical examination is otherwise normal and the vertigo responds to treatment, advanced imaging is not indicated.
- MRI Brain without and with contrast with attention to internal auditory canals (CPT® 70553) is indicated for the following:
 - ◆ Vertigo with associated headache or ataxia.
 - ◆ Vertigo associated with tinnitus and/or hearing loss.
 - ◆ Vertigo that does not respond to vestibular treatment.

Background and Supporting Information

- Isolated vertigo is an uncommon complaint during childhood. Middle ear/Eustachian tube problems are the most common cause of isolated vertigo in children.

Tinnitus (PEDHD-16.5)

- Children with hearing loss and tinnitus should be imaged according to **Hearing Loss (PEDHD-16.1)**. A pertinent evaluation including a detailed history, physical examination (including otoscopic examination), and age-appropriate audiology testing should be performed on any child with known or suspected tinnitus prior to considering advanced imaging.
- Advanced imaging is not indicated in the overwhelming majority of pediatric individuals with isolated tinnitus and normal hearing.
- CT Temporal Bone without contrast (CPT® 70480) or without and with contrast (CPT® 70482), OR MRI Brain without and with contrast with attention to internal auditory canals (CPT® 70553), OR MRI Orbits/Face/Neck without and with contrast (CPT® 70543) is indicated for the following:
 - ◆ Clinical suspicion of mass lesion causing tinnitus.
 - ◆ Persistent tinnitus after recent significant trauma.
 - ◆ Persistent unilateral tinnitus.
- MRA Head (CPT® 70544, CPT® 70545 or CPT® 70546) or CTA Head (CPT® 70496) AND/OR MRA Neck (CPT® 70547, CPT® 70548 or CPT® 70549) or CTA Neck (CPT® 70498) for Pulsatile tinnitus or suspicion for vascular lesions

Background and Supporting Information

- Tinnitus without hearing loss is a less common complaint during childhood.

References

1. Haddad J, and Dodhia SN. The ear. Nelson Textbook of Pediatrics, Chapter 654. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21st edition. 2020, pp 3398-3400.
2. Expert Panel on Neurologic Imaging:, Sharma A, Kirsch CFE, et al. ACR Appropriateness Criteria® Hearing Loss and/or Vertigo. J Am Coll Radiol. 2018;15(11S):S321-S331. doi:10.1016/j.jacr.2018.09.020
3. Minovi A, and Dazert S. Diseases of the middle ear in childhood. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2014 Dec; 13:1-29.
4. Kerr R, Kang E, Hopkins B, Anne S. Pediatric tinnitus: Incidence of imaging anomalies and the impact of hearing loss. International Journal of Pediatric Otorhinolaryngology. 2017;103:147-149.
5. Jahn K. Vertigo and dizziness in children. Handbook of Clinical Neurology Neuro-Otology. 2016:353-363. doi:10.1016/b978-0-444-63437-5.00025-x.
6. Shekdar KV, Bilaniuk LT. Imaging of Pediatric Hearing Loss. Neuroimaging Clinics of North America. 2019;29(1):103-115. doi:10.1016/j.nic.2018.09.011.
7. ACR-ASNR-SPR Practice Parameter for the Performance of Computed Tomography (CT) of the Extracranial Head and Neck Revised 2021. (Resolution 5). <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/CT-Head-Neck>.
8. Rosenfeld RM, Shin JJ, Schwartz SR, et al. Clinical Practice Guideline: Otitis Media with Effusion (Update). Otolaryngology–Head and Neck Surgery. 2016;154(1_suppl). doi:10.1177/0194599815623467.
9. Rosenfeld RM, Schwartz SR, Cannon CR, et al. Clinical Practice Guideline. Otolaryngology–Head and Neck Surgery. 2014;150(1_suppl). doi:10.1177/0194599813517083
10. Rosenfeld RM, Schwartz SR, Pynnonen MA, et al. Clinical practice guideline: Tympanostomy tubes in children. Otolaryngol Head Neck Surg. 2013;149(1 Suppl):S1-S35. doi:10.1177/0194599813487302
11. Expert Panel on Neurologic Imaging:, Kessler MM, Moussa M, et al. ACR Appropriateness Criteria® Tinnitus. J Am Coll Radiol. 2017;14(11S):S584-S591. doi:10.1016/j.jacr.2017.08.052
12. Lieu JEC, Kenna M, Anne S, Davidson L. Hearing Loss in Children: A Review. JAMA. 2020 Dec 1;324(21):2195-2205. doi: 10.1001/jama.2020.17647.
13. Aylward SC, Reem RE. Pediatric Intracranial Hypertension. Pediatr Neurol. 2017 Jan;66:32-43. doi: 10.1016/j.pediatrneurol.2016.08.010
14. Ropers FG, Pham ENB, Kant SG, et al. Assessment of the Clinical Benefit of Imaging in Children With Unilateral Sensorineural Hearing Loss: A Systematic Review and Meta-analysis. JAMA Otolaryngol Head Neck Surg. 2019;145(5):431-443. doi:10.1001/jamaoto.2019.0121
15. Campion T, Taranath A, Pinelli L, et al. Imaging of temporal bone inflammations in children: a pictorial review. Neuroradiology. 2019;61(9):959-970. doi:10.1007/s00234-019-02258-1.

Autism Spectrum Disorders (PEDHD-17)

Autism Spectrum Disorders (PEDHD-17.1)

- The group of diagnoses, including Asperger syndrome, are classified as pervasive development disorders (PDD). These diagnoses are established on clinical criteria, and no imaging study can confirm the diagnosis.
- Comprehensive evaluation for autism might include history, physical exam, audiology evaluation, speech, language, and communication assessment, cognitive and behavioral assessments, and academic assessment.
- MRI Brain without and with contrast (CPT® 70553) is indicated for new or worsening focal neurologic findings documented on a pertinent physical. Consider advanced imaging if there is loss of developmental milestones and/or regression in two or more areas of development.
- PET imaging is considered investigational in the evaluation of individuals with autism spectrum disorders.

References

1. Bridgemohan CF. Autism spectrum disorder. Nelson Textbook of Pediatrics, Chapter 54. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21st edition. 2020, pp 294-302.
2. Baker E, and Jeste SS. Diagnosis and Management of Autism Spectrum Disorder in the Era of Genomics. *Pediatric Clinics of North America*. 2015;62(3):607-618. doi:10.1016/j.pcl.2015.03.003.
3. Zürcher NR, Bhanot A, McDougale CJ, Hooker JM. A systematic review of molecular imaging (PET and SPECT) in autism spectrum disorder: Current state and future research opportunities. *Neuroscience & Biobehavioral Reviews*. 2015;52:56-73. doi:10.1016/j.neubiorev.2015.02.002.

Behavioral and Psychiatric Disorders (PEDHD-18)

Behavioral and Psychiatric Disorders (PEDHD-18.1)

- Behavioral and psychiatric disorders of childhood or adolescence, to include Attention Deficit Hyperactivity Disorder (ADHD), generally require no advanced imaging for diagnosis or management.²
 - ◆ MRI Brain without and with contrast (CPT® 70553) is indicated for new or worsening focal neurologic findings.
- For concerns of PANS (Pediatric acute-onset neuropsychiatric syndrome) and PANDAS (Pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection) See **Movement Disorders including Tourette's Syndrome (PEDHD-26)**

Reference

1. Behavioral and Psychiatric Disorders. *Nelson Textbook of Pediatrics, Part III, Behavioral and Psychiatric Disorders. Chapters 32-47.* eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21st edition. 2020, pp 124-191
2. Pereira-Sanchez V, Castellanos FX. Neuroimaging in attention-deficit/hyperactivity disorder. *Curr Opin Psychiatry.* 2021;34(2):105-111. doi:10.1097/YCO.0000000000000669.

Developmental Disorders (PEDHD-19)	
Intellectual Disability (PEDHD-19.1)	76
Cerebral Palsy (PEDHD-19.2)	76
Developmental Motor Delay (PEDHD-19.3)	76
Neurometabolic and Neurogenetic Disorders (PDHD-19.4)	77

Intellectual Disability (PEDHD-19.1)

- MRI Brain without and with contrast (CPT® 70553) is indicated for new or worsening focal neurologic findings and/or new or worsening cognitive decline.⁹

Background and Supporting Information

- Intellectual disability may be primary or secondary to a variety of heterogeneous disorders.
- Intellectual disability is a condition characterized by significant limitations in both intellectual functioning and adaptive behavior that originates before the age of 22.¹³ One way to measure intellectual functioning is an IQ test. Generally, an IQ test score of around 70 or as high as 75 indicates a significant limitation in intellectual functioning.¹³

Cerebral Palsy (PEDHD-19.2)

- Cerebral palsy is a static motor encephalopathy caused by a variety of entities spanning developmental, metabolic, genetic, infectious, ischemic, and other acquired etiologies.
- MRI Brain without and with contrast (CPT® 70553) is indicated for:
 - ◆ Initial evaluation of newly diagnosed cerebral palsy.
 - ◆ New or worsening focal neurologic findings documented on a physical examination, including the presence of developmental delay.
 - ◆ Re-evaluation after 24 months of age due to rapid myelination during the first 2 years of life
- For spinal imaging requests See **Myelopathy (SP-7.1)** in the Spine Imaging Guidelines

Background and Supporting Information

- Many individuals with intellectual disability also have cerebral palsy, but not all individuals with cerebral palsy have intellectual disability.

Developmental Motor Delay (PEDHD-19.3)

- There are many causes for developmental motor delay. Individuals with motor delay can have decreased, normal, or increased muscular tone. Individuals with normal tone do not require imaging unless they have focal neurologic findings.
- MRI Brain without and with contrast (CPT® 70553) is indicated for:
 - ◆ Initial evaluation of newly diagnosed developmental motor delay with abnormal muscle tone.
 - ◆ Toe walking, when associated with upper motor neuron signs including hyperreflexia, abnormal tone (spasticity/hypotonia), or positive Babinski sign.
 - ◆ New or worsening focal neurologic findings.
 - ◆ Re-evaluation after 24 months of age due to rapid myelination during the first 2 years of life
- For spinal imaging requests See **Myelopathy (SP-7.1)** in the Spine Imaging Guidelines and **Tethered Cord (PEDSP-5)** in the Pediatric Spine Imaging Guidelines

Neurometabolic and Neurogenetic Disorders (PEDHD-19.4)

Imaging Supported	Indications	Suspected or known Neurometabolic and/or neurogenetic disorders, but not limited to
MRI Brain without and with contrast (CPT® 70553) OR MRI Brain without contrast (CPT® 70551) AND/OR Magnetic Resonance Spectroscopy (MRS, CPT® 76390)	Requested by a neurologist or geneticist, or any provider in consultation with a neurologist or geneticist, for: <ul style="list-style-type: none"> ◆ Initial evaluation AND/OR ◆ Disease monitoring AND/OR ◆ New or worsening symptoms AND/OR ◆ Change in therapy is being considered 	<ul style="list-style-type: none"> ➤ X-linked adrenoleukodystrophy (X-ALD, CALD) ➤ Canavan disease ➤ Creatine deficiency ➤ Nonketotic hyperglycinemia ➤ Maple Syrup Urine disease ➤ Metachromatic Leukodystrophy (MCL) ➤ Pelizaeus-Merzbacher disease (PMD) ➤ Hypomyelination and Congenital Cataract ➤ Globoid Cell Leukodystrophy (Krabbe disease) ➤ Mitochondrial disorders (such as, but not limited to Leigh's syndrome, Kearns-Sayre syndrome, Mitochondrial Encephalopathy with Lactic Acidosis and Stroke-Like Episodes (MELAS)) ➤ Alexander disease (ALX, AXD, dysmyelinogenic leukodystrophy) ➤ Megalencephalic leukoencephalopathy with subcortical cysts ➤ Vanishing White Matter (VWM) disease (Leukoencephalopathy with VWM, Childhood Ataxia with CNS Hypomyelination (CACH) syndrome)

References

- Shapiro BK, and O'Neil ME. Intellectual Disability. Nelson Textbook of Pediatrics, Chapter 53. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21st edition. 2020, pp 283-294.
- Johnston MV. Encephalopathies. *Nelson Textbook of Pediatrics, Chapter 616.1*. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21st edition. 2020, pp 3186-3173
- Noritz GH, and Murphy NA. Motor delays: early identification and evaluation. *Pediatrics*. 2013 May; 131 (6).
- Murias K, Moir A, Myers KA, Liu I, Wei X-C. Systematic review of MRI findings in children with developmental delay or cognitive impairment. *Brain and Development*. 2017;39(8):644-655.
- Haynes KB, Wimberly RL, Vanpelt JM, Jo C-H, Riccio AI, Delgado MR. Toe Walking. *Journal of Pediatric Orthopaedics*. 2018;38(3):152-156.
- Sanyal S, et.al. Magnetic Resonance Imaging of Brain in Evaluation of Floppy Children: A Case Series. *Iran J Child Neurol*. 2015 Autumn; 9(4):65-74. PMID: PMC4670981 PMID: 26664445.
- Ali AS, et al. Magnetic Resonance Imaging (MRI) Evaluation of Developmental Delay in Pediatric Patients. *J Clin Diagn Res*. 2015 Jan; 9(1): TC21-TC24. doi: 10.7860/JCDR/2015/11921.5478.
- Barkovich AJ. Magnetic resonance techniques in the assessment of myelin and myelination. *Journal of Inherited Metabolic Disease*. 2005;28(3):311-343. doi:10.1007/s10545-005-5952-z
- Bonkowsky JL, Keller S; AAP Section on Neurology, Council on Genetics. Leukodystrophies in Children: Diagnosis, Care, and Treatment. *Pediatrics*. 2021;148(3):e2021053126. doi:10.1542/peds.2021-053126
- Mankad K, Talenti G, Tan AP, et al. Neurometabolic Disorders of the Newborn. *Top Magn Reson Imaging*. 2018;27(4):179-196. doi:10.1097/RMR.0000000000000176
- Whitehead MT, Lai LM, Blüml S. Clinical 1H MRS in childhood neurometabolic diseases - part 2: MRS signatures. *Neuroradiology*. 2022;64(6):1111-1126. doi:10.1007/s00234-022-02918-9
- Aida N. 1H-MR Spectroscopy of the Early Developmental Brain, Neonatal Encephalopathies, and Neurometabolic Disorders. *Magn Reson Med Sci*. 2022;21(1):9-28. doi:10.2463/mrms.rev.2021-0055
- American Association on Intellectual and Developmental Disabilities. Defining Criteria for Intellectual Disability. Aaidd.org. Published 2019. <https://www.aaidd.org/intellectual-disability/definition>

Ataxia (PEDHD-20)

Ataxia (PEDHD-20.1)

- See **Developmental Disorders (PEDHD-19)**.
- A pertinent evaluation including a detailed history, physical examination with a thorough neurologic examination, and appropriate laboratory studies should be performed prior to considering advanced imaging, unless the individual is undergoing guideline-supported scheduled follow-up imaging evaluation or request is from or in consultation with a neurologist or neurosurgeon who has seen the individual since onset of symptoms.
- MRI Brain without and with contrast (CPT® 70553) can be performed to evaluate ataxia, hereditary ataxia, and slowly progressive ataxia.
 - ◆ If spinal etiology is suspected the following may be indicated:
 - MRI Cervical Spine (CPT® 72141 or CPT® 72156) and/or
 - MRI Thoracic Spine (CPT® 72146 or CPT® 72157) and/or
 - MRI Lumbar Spine (CPT® 72148 or CPT® 72158)
- CT Head without and with contrast (CPT® 70470) or with contrast (CPT® 70460) is indicated for individuals who have a contraindication to MRI.
 - ◆ CT should not be used in place of MRI solely to avoid sedation in young children because MRI is superior for imaging the posterior fossa.
 - ◆ If there is a contraindication to contrast and a spinal etiology is suspected the following may be indicated:
 - CT Cervical Spine (CPT® 72125 or CPT® 72127) and/or
 - CT Thoracic Spine (CPT® 72128 or CPT® 72130) and/or
 - CT Lumbar Spine (CPT® 72131 or CPT® 72133)
- CT Head without contrast (CPT® 70450) or without and with contrast (CPT® 70470) or MRI Brain without contrast (CPT® 70551) or without and with contrast (CPT® 70553) is indicated for individuals with acute ataxia following significant head trauma.
- Repeat imaging may be appropriate no more frequently than every 12 months when requested by a specialist or any provider in consultation with a specialist unless there are new signs or symptoms.

Background and Supporting Information

- Ataxia refers to an abnormally ill-coordinated or unsteady gait for age. “Limb ataxia” refers to impaired coordination (for age) of limbs, especially arms. Developmental failure to acquire the ability to walk is a form of developmental delay, not ataxia.

References

1. Expert Panel on Neurologic Imaging; Juliano AF, Policeni B, et al. ACR Appropriateness Criteria® Ataxia. J Am Coll Radiol. 2019;16(5S):S44-S56. doi:10.1016/j.jacr.2019.02.021
2. Salman MS, Chodirker BN, Bunge M. Neuroimaging Findings and Repeat Neuroimaging Value in Pediatric Chronic Ataxia. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 2016;43(06):824-832.
3. Vedolin L, Gonzalez G, Souza C, Lourenço C, Barkovich A. Inherited Cerebellar Ataxia in Childhood: A Pattern-Recognition Approach Using Brain MRI. American Journal of Neuroradiology. 2012;34(5):925-934. doi:10.3174/ajnr.a3055.
4. Alves CAPF, Fragoso DC, Gonçalves FG, Marussi VH, Amaral LLFD. Cerebellar Ataxia in Children. Topics in Magnetic Resonance Imaging. 2018;27(4):275-302. doi:10.1097/rmr.000000000000175.
5. Morrison PE and Mink JW. Ataxias. Nelson Textbook of Pediatrics, Chapter 615.1 eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21st edition. 2020, pp 3151-3155.

Epistaxis (PEDHD-21)

Imaging (PEDHD-21.1)

- Initial evaluation of epistaxis (nosebleed), including recurrent epistaxis that is refractory to medical management is by direct or endoscopic visualization of the relevant portions of the upper airway.
- If a mass lesion is detected on direct visualization, any ONE of the following imaging studies is indicated:
 - ◆ CT Maxillofacial without contrast (CPT® 70486) or without and with contrast (CPT® 70488).
 - ◆ MRI Orbits/Face/Neck without and with contrast (CPT® 70543).

References

1. Haddad J, and Keesecker S. Acquired disorders of the nose. *Nelson Textbook of Pediatrics, Chapter 405.2*. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21st edition. 2020, pp 2183-2084.
2. Trunkel DE, Anne S, Payne SC, et al. Clinical Practice Guideline: Nosebleed (Epistaxis). *Otolaryngology–Head and Neck Surgery*. 2020;162(1_suppl). doi:10.1177/0194599819890327.
3. ACR-ASNR-SPR Practice Parameter for the Performance of Computed Tomography (CT) of the Extracranial Head and Neck Revised 2021. (Resolution 5). <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/CT-Head-Neck>.

Pseudotumor Cerebri (PEDHD-22)

Pseudotumor Cerebri (PEDHD-22.1)

- Pseudotumor cerebri indications in pediatric individuals are identical to those for adult individuals. See **Papilledema/Pseudotumor Cerebri (HD-17.1)** in the Head Imaging Guidelines.

Cranial Neuropathies (PEDHD-23)

Cranial Neuropathies (PEDHD-23.1)

- MRI Brain without and with contrast (CPT® 70553) is indicated for all individuals with new or worsening specific cranial nerve abnormalities.
- MRI Neck without and with contrast (CPT® 70543) is also indicated for individuals with abnormalities in cranial nerves IX, X, XI, or XII.

References

1. Expert Panel on Neurologic Imaging:, Policeni B, Corey AS, et al. ACR Appropriateness Criteria® Cranial Neuropathy. *J Am Coll Radiol*. 2017;14(11S):S406-S420. doi:10.1016/j.jacr.2017.08.035.
2. Rubin M. Overview of neuro-ophthalmologic and cranial nerve disorders. Merck Manual. Last Modified September 2020. <https://www.merckmanuals.com/professional/neurologic-disorders/neuro-ophthalmologic-and-cranial-nerve-disorders/overview-of-neuro-ophthalmologic-and-cranial-nerve-disorders>.
3. Janowski AB and Hunstad DA. Central Nervous System Infections. Nelson Textbook of Pediatrics, Chapter 621. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21st edition. 2020, pp 3223-3234.

Pediatric Sleep Disorders (PEDHD-24)

Pediatric Sleep Disorders (PEDHD-24.1)

- See **Pediatric Sleep Guidelines (SL-3)** in the Sleep Apnea and Treatment Clinical Guidelines.
- Advanced imaging is not indicated for the following:
 - ◆ Parasomnias.
 - ◆ Bed wetting (if child is otherwise neurologically normal).
 - ◆ Insomnia.
 - ◆ Narcolepsy.
 - ◆ Restless Leg Syndrome (polysomnography is useful).
- For Obstructive Sleep Apnea, endoscopic examination of the upper airway and lateral upper airway x-rays should be performed initially.
 - ◆ CT Maxillofacial without contrast (CPT® 70486) may be indicated for evaluation of obstructive anatomy if operative intervention is being considered.
- For Central Sleep Apnea, MRI Brain without contrast (CPT® 70551) or without and with contrast (CPT® 70553) is indicated if the clinical picture and/or polysomnography study suggests central sleep apnea.
- There is no indication for imaging prior to tonsillectomy for obstructive sleep apnea

Reference

1. Owens JA. Sleep medicine. Nelson Textbook of Pediatrics, Chapter 31. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21st edition. 2020, pp 172-184.
2. Mitchell RB, Archer SM, Ishman SL, et al. Clinical Practice Guideline: Tonsillectomy in Children (Update). Otolaryngology–Head and Neck Surgery. 2019;160(1_suppl). doi:10.1177/0194599818801757.

Temporomandibular Joint (TMJ)/Dental/Maxillofacial Imaging in Children (PEDHD-25)

Temporomandibular Joint Imaging (PEDHD-25.1)	84
Dental/Periodontal/Maxillofacial Imaging (PEDHD 25.2)	84

Temporomandibular Joint Imaging (PEDHD-25.1)

- Temporomandibular Joint (TMJ) Imaging in Children indications in pediatric individuals are very similar to those for adult individuals. See **Temporomandibular Joint Disease (TMJ) (HD-30.1)** in the Head Imaging Guidelines.
- Pediatric-specific imaging considerations include the following:
 - ◆ There is a paucity of clinical symptoms and poor sensitivity of conventional x-rays in diagnosing TMJ arthritis in pediatric individuals with arthritis
 - MRI TMJ (CPT® 70336) is indicated annually for detecting silent TMJ arthritis in children with juvenile idiopathic arthritis (JIA).
 - Bone Scintigraphy/Bone Scan 3 Phase Study (CPT® 78315) in individuals over 12 years of age⁷ is appropriate in anticipation or consideration of surgery⁷
 - Unilateral condylar hyperplasia is manifested by slow growth in areas of the mandible causing facial asymmetry. It is usually a self-limiting condition seen predominantly in 12–30 year olds.

Dental/Periodontal/Maxillofacial Imaging (PEDHD 25.2)

See **Dental/Periodontal/Maxillofacial Imaging (HD 30.2)**

References

1. Zwir LM, Terreri MT, Sousa SA, et al. Are temporomandibular joint signs and symptoms associated with magnetic resonance imaging findings in juvenile idiopathic arthritis patients? A longitudinal study. *Clin Rheumatol*. 2015 Dec; 34 (12) 057-2063.
2. Navallas M, Inarejos EJ, Iglesias E, Lee GYC, Rodríguez N, Antón J. MR Imaging of the Temporomandibular Joint in Juvenile Idiopathic Arthritis: Technique and Findings. *RadioGraphics*. 2017;37(2):595-612. doi:10.1148/rg.2017160078.
3. Stoll ML, Kau CH, Waite PD, Cron RQ. Temporomandibular joint arthritis in juvenile idiopathic arthritis, now what? *Pediatric Rheumatology*. 2018;16(1).
4. Miller E, Clemente EJ, Tzaribachev N, et al. Imaging of temporomandibular joint abnormalities in juvenile idiopathic arthritis with a focus on developing a magnetic resonance imaging protocol. *Pediatric Radiology*. 2018;48(6):792-800. doi:10.1007/s00247-017-4005-8.
5. Hammer MR, Kanaan Y. Imaging of the Pediatric Temporomandibular Joint. *Oral and Maxillofacial Surgery Clinics of North America*. 2018;30(1):25-34. doi:10.1016/j.coms.2017.08.008.
6. Wu EY and Rabinovich CE. Juvenil Idiopathic Arthritis. *Nelson Textbook of Pediatrics*, Chapter 180. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21st edition. 2020, pp 1260-1268
7. Lee YH, Hong IK, Chun YH. Prediction of painful temporomandibular joint osteoarthritis in juvenile patients using bone scintigraphy. *Clin Exp Dent Res*. 2019;5(3):225-235. Published 2019 Mar 15. doi:10.1002/cre2.175 <https://onlinelibrary.wiley.com/doi/epdf/10.1002/cre2.175>.

Movement Disorders including Tourette's Syndrome (PEDHD-26)

Tourette's Syndrome (PEDHD-26.1)	86
Movement Disorders (PEDHD-26.2)	86

Tourette's Syndrome (PEDHD-26.1)

- The diagnosis of Tourette's syndrome is made clinically and advanced neuroimaging is not indicated for either diagnosis or management.

Movement Disorders (PEDHD-26.2)

- Movement disorders are hyperkinetic and hypokinetic movements that are involuntary. The majority are diagnosed based on a clinical diagnosis and do not require imaging.
- Typically Benign Movement disorders include:
 - ◆ Stereotypies, repetitive rhythmic movements
 - ◆ Tics that are vocal or motor with typical onset and course
 - ◆ Tourette Syndrome
 - ◆ Essential Tremor or tremors of anxiety or weakness
 - ◆ Restless Leg Syndrome
- MRI Brain without contrast (CPT® 70551), or without and with contrast (CPT® 70553) is considered in the following clinical scenarios:
 - ◆ Atypical clinical features for example, movements that persist in sleep, onset outside of typical age at onset (4-6 years for tics) , rapid progression, incomplete or uncertain medication responsiveness, or clinical diagnostic uncertainty, limbic encephalitis
 - ◆ Dystonia, intermittent involuntary muscle contractions
 - ◆ Chorea, continual irregular movements
 - ◆ Ballism, involuntary high amplitude movements
 - ◆ Athetosis, slow writhing continuous movements
 - ◆ Myoclonus, involuntary muscle jerks (not sleep myoclonus)
- For concerns of PANS (Pediatric acute-onset neuropsychiatric syndrome) and PANDAS (Pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection), MRI Brain without contrast (CPT® 70551), or without and with contrast (CPT® 70553) may be considered only after a complete medical workup including labs, acute infection, and other comorbid psychiatric disorders (e.g. OCD, ADHD and ASD) have been investigated as routine brain imaging is not routinely recommended.
- See **Movement Disorders (HD-15.1)** in the Head Imaging Guidelines for the following:
 - ◆ Suspected Huntington Disease
 - ◆ Evaluation for surgical treatment of Essential Tremor or Parkinson's disease, including Deep Brain Stimulator (DBS) placement
- Post-op imaging is approvable when ordered by a specialist or any provider in consultation with a specialist for either procedure.

Background and Supporting Information

- There is little evidence to support the use of MRA/CTA and PET in the evaluation of movement disorders.
- Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. The first symptoms of TS are almost always noticed in childhood. Some of the more common tics include eye blinking and other vision irregularities, facial grimacing, shoulder shrugging, and head or shoulder jerking. Perhaps the most dramatic and disabling tics are those that result in self-harm such as punching oneself in the face, or vocal tics including coprolalia (uttering swear words) or echolalia (repeating the words or phrases of others). Many with TS experience additional neurobehavioral problems including inattention, hyperactivity and impulsivity, and obsessive-compulsive symptoms such as intrusive thoughts/worries and repetitive behaviors.

Reference: <https://www.ninds.nih.gov/Disorders/All-Disorders/Tourette-Syndrome-Information-Page>

References

1. Serajee FJ, and Mahbubl AHM. Advances in tourette syndrome diagnosis and treatment. *Pediatr Clin N Am*. 2015 June; 62 (3): 687-701.
2. Zinner SH, Mink JW. Movement Disorders I: Tics and Stereotypies. *Pediatrics in Review*. 2010;31(6):223-233. doi:10.1542/pir.31-6-223.
3. Jonathon W. Mink, Movement Disorders. *Nelson Textbook of Pediatrics*, Chapter 615. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21st edition 2020, pp 143-144.
4. Colleen Ryan, Heather Walter, David DeMaso, Tic Disorders. *Nelson Textbook of Pediatrics*, Chapter 37.1. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21st edition 2020, pp 206-208.
5. Frankovich J, Swedo S, Murphy T, et al. Clinical Management of Pediatric Acute-Onset Neuropsychiatric Syndrome: Part II—Use of Immunomodulatory Therapies. *Journal of Child and Adolescent Psychopharmacology*. 2017;27(7):574-593. doi:10.1089/cap.2016.0148.
6. Cooperstock MS, Swedo SE, Pasternack MS, Murphy TK, Consortium FTP. Clinical Management of Pediatric Acute-Onset Neuropsychiatric Syndrome: Part III—Treatment and Prevention of Infections. *Journal of Child and Adolescent Psychopharmacology*. 2017;27(7):594-606. doi:10.1089/cap.2016.0151.
7. Thienemann M, Et.al. Clinical Management of Pediatric Acute-Onset Neuropsychiatric Syndrome: Part 1- Psychiatric and Behavioral Interventions. *Journal of Child and Adolescent Psychopharmacology*, 27(7), 2017, pp. 556-573. <https://doi.org/10.1089/cap.2016.0145>.

Tuberous Sclerosis (PEDHD-27)

Tuberous Sclerosis (PEDHD-27.1)

- See Tuberous Sclerosis Complex (TSC) (PEDONC-2.9) in the Pediatric Oncology Imaging Guidelines.

Von Hippel Lindau Syndrome (VHL) (PEDHD-28)

Von Hippel-Lindau Syndrome (VHL) (PEDHD-28.1)

- See Von Hippel-Lindau Syndrome (VHL) (PEDONC-2.10) in the Pediatric Imaging Guidelines.

CNS Infection (PEDHD-29)

CNS Infection (PEDHD-29.1)

- CNS infection imaging indications in pediatric individuals are similar to those for adult individuals. See **CNS and Head Infection/ Neuro-COVID-19 (HD-14)** in the Head Imaging Guidelines.
- CT Head (as per **General Guidelines – CT Head (HD-1.4)** in the Head Imaging Guidelines) may be considered in Pediatric CNS Infection.
- The following studies may be considered for suspected intracranial infection if any signs of CNS infection are present:
 - ◆ MRI Brain without and with contrast (CPT® 70553) (preferred) or MRI Brain without contrast (CPT® 70551)
 - ◆ CT Head (CPT® 70450, CPT® 70460, or CPT® 70470) in cases where MRI is contraindicated or urgently prior to lumbar puncture to rule out meningitis.
- Pediatric-specific imaging considerations include suspected congenital brain infection and neonatal meningitis. The common causes of prenatal infections of the central nervous system are cytomegalovirus, *Toxoplasma gondii*, herpes simplex type 2 virus and most recently zika virus. The findings suggesting prenatal brain infection include microcephaly, microphthalmia, chorioretinitis, cataracts, hypotonia, and seizures. The following are performed for congenital brain infections:
 - ◆ The following imaging is considered for newborn infants with suspected prenatal brain infection regardless of inciting organism. (For additional information see CDC's Areas with risk of Zika site: <https://wwwnc.cdc.gov/travel/page/zika-information>)
 - Ultrasound Head (CPT® 76506) can be approved as an initial imaging study.
 - MRI Brain without and with contrast (CPT® 70553) is indicated if the ultrasound is abnormal.
 - ◆ Newborn infants with microcephaly should be evaluated as discussed in **Macrocephaly, Microcephaly, and Hydrocephalus (PEDHD-7)**.
- Neonatal meningitis is most often caused by bacterial pathogens and usually occurs as a complication of sepsis in the first week of life. In older infants and children, meningeal inoculation occurs secondary to hematogenous spread or penetrating trauma.
- The following imaging is considered for newborns or older infants with and open fontanelle and suspected meningitis.
 - ◆ Ultrasound Head (CPT® 76506) as an initial imaging study, but is not required.
 - ◆ MRI Brain without and with contrast (CPT® 70553) is indicated if the ultrasound is abnormal

- A wide spectrum of neurological diseases have been observed in children with COVID-19 infection in children including, but not limited to, Multisystem Inflammatory Syndrome and Acute Necrotising Myelitis.^{10,11}
 - ◆ MRI Brain with and without contrast (CPT® 70553) and/or MRI Cervical Spine without and with contrast (CPT® 72156) and/or MRI Thoracic Spine with and without contrast (CPT® 72157) and/or MRI Lumbar Spine without and with contrast (CPT® 72158)
- Metabolic (FDG) Brain PET (CPT® 78608) is appropriate to evaluate individuals suspected of having encephalitis, including autoimmune encephalitis, if diagnosis remains unclear after evaluation with MRI Brain, CSF analysis, and lab testing including serology.¹²

References

1. Hedlund G, Bale JE, Barkovich AJ. Infections of the developing and mature nervous system. In: Barkovich AJ, Raybaud C, eds. *Pediatric Neuroimaging*, 6th ed. Philadelphia PA: Wolters Kluwer. 2019; 1072-1176.
2. De Vries LS, and Volpe JJ. Viral, protozoan, and related intracranial infections. In: Volpe JJ, ed. *Volpe's Neurology of the Newborn*. 6th ed. Philadelphia: Elsevier. 2018; 973-1049.
3. Melo AS, Aguiar RS, Amorim MM, et al. Congenital Zika Virus Infection: Beyond Neonatal Microcephaly. *JAMA Neurol*. 2016;73(12):1407-1416. doi:10.1001/jamaneurol.2016.3720
4. Levine D, Jani JC, Castro-Aragon I, et al. How does imaging of congenital Zika compare with imaging of other TORCH infections? *Radiology*. 2017; 285: 744-761.
5. De Oliveria Melo AS, Aguiar RS, Amorim MM, et al. Congenital Zika virus infection: beyond neonatal microcephaly. *JAMA Neurol*. 2016 Dec 1; 73: 1407-1416.
6. Vepraskas SA. Zika Virus – an emerging arbovirus associated with fetal abnormalities. CDC's response to Zika.
7. Rabe I, Meaney-Delman D, and Moore CA. "Zika Virus – What Clinicians Need to Know." clinician outreach and communication activity call. Centers for Disease Control and Prevention. 26 Jan. 2016. Available at: http://coursewareobjects.elsevier.com/objects/elr/ExpertConsult/Kliegman/nelson20e/updates/CDC_presentation_01262016.pdf.
8. Janowski AB and Hunstad DA. Central Nervous System Infections. *Nelson Textbook of Pediatrics*, Chapter 621. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21st edition. 2020, pp 3223-3234.
9. ACR-ASNR-SPR Practice Parameter for the Performance of Computed Tomography (CT) of the Extracranial Head and Neck Revised 2021. (Resolution 5). <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/CT-Head-Neck>
10. Mun-Ching Wong A, Toh CH. Spectrum of neuroimaging mimics in children with COVID-19 infection [published online ahead of print, 2021 Nov 15]. *Biomed J*. 2021;S2319-4170(21)00151-7. doi:10.1016/j.bj.2021.11.005 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591861/pdf/main.pdf>
11. Lindan CE, Mankad K, Ram D, et al. Neuroimaging manifestations in children with SARS-CoV-2 infection: a multinational, multicentre collaborative study. *Lancet Child Adolesc Health*. 2021;5(3):167-177. doi:10.1016/S2352-4642(20)30362-X <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744016/pdf/main.pdf>
12. Probasco JC, Solnes L, Nalluri A, et al. Abnormal brain metabolism on FDG-PET/CT is a common early finding in autoimmune encephalitis. *Neurology - Neuroimmunology Neuroinflammation*. 2017;4(4). doi:10.1212/nxi.0000000000000352.

Scalp and Skull Lesions (PEDHD-30)

Scalp and Skull Lesions (PEDHD-30.1)

- Scalp and skull lesion imaging indications in pediatric individuals are identical to those for adult individuals with the exception of neonates. See **Scalp and Skull Lesions (HD-20.1)** in the Head Imaging Guidelines.
- The following imaging is considered for newborns with palpable scalp and skull lesions.
 - ◆ Ultrasound Head (CPT® 76506) can be approved as an initial imaging study.
 - ◆ MRI Brain without and with contrast (CPT® 70553) (preferred) or CT Head without and with contrast (CPT® 70470) is indicated if the ultrasound is abnormal and associated anomalies are suspected.

Background and Supporting Information

- In neonates and young infants, scalp masses include:
 - ◆ Congenital lesions (cephalocele-discussed above, dermoid cysts, epidermoid cyst)
 - ◆ Vascular lesions (hemangioma, sinus pericranii)
 - ◆ Extracranial hemorrhage related to birth trauma (caput succedaneum, cephalohematoma, subgaleal hematoma)
 - ◆ After the first year of life, malignant tumors, such as Langerhans cell histiocytosis metastases from neuroblastoma and rhabdomyosarcoma are an additional cause of a scalp mass

References

1. Siegel MJ. Brain. In: *Pediatric sonography*. 5th ed. Philadelphia. Wolters Kluwer. 2018. 40-111.
2. Bansal AG, Oudsema R, Masseaux JA, Rosenberg HK. US of Pediatric Superficial Masses of the Head and Neck. *RadioGraphics*. 2018;38(4):1239-1263. doi:10.1148/rg.2018170165.
3. Carratalá RM, Cabezuelo MEC, Herrera IH, et al. Nontraumatic Lesions of the Scalp: Practical Approach to Imaging Diagnosis: Neurologic/Head and Neck Imaging. *RadioGraphics*. 2017;37(3):999-1000. doi:10.1148/rg.2017160112.
4. Kollipara R, Dinneen L, Rentas KE, et al. Current Classification and Terminology of Pediatric Vascular Anomalies. *American Journal of Roentgenology*. 2013;201(5):1124-1135. doi:10.2214/ajr.12.10517.
5. Landisch S. Hemophagocytic Lymphohistiocytosis. *Nelson Textbook of Pediatrics*, Chapter 534.2. eds Kliegman RM, St. Geme JW III, Blum NJ, Shah SS, Tasker RC, Wilson KM. 21st edition. 2020, pp 2712-2713.
6. Robinson AJ, Blaser S and Fink AM. Prenatal Imaging. *Caffey's Pediatric Diagnostic Imaging*, Chapter 19. Coley BR, et al. 13th edition. 2019, pp 158-161.
7. Tobler JF, Slovis, TL and Rozzelle AA, Selected Craniofacial Syndromes, and Other Abnormalities of the Skull. *Caffey's Pediatric Diagnostic Imaging*, Chapter 20. Coley BR, et al. 13th edition. 2019, pp 162-180.

Eye Disorders (PEDHD-31)

Eye Disorders (PEDHD-31.1)

- Eye disorder imaging indications in pediatric individuals are close to identical to those for adult individuals. See **Eye Disorders and Visual Loss (HD-32.1)** in the Head Imaging Guidelines.
- For specific pediatric conditions: MRI Orbits without contrast (CPT® 70540) or MRI Orbits without and with contrast (CPT® 70543) or CT Orbits with contrast (CPT® 70481) or CT Orbits without contrast (CPT® 70480) and/or MRI Brain without contrast (CPT® 70551) or MRI with and without contrast (CPT® 70553)² can be performed for Optic Nerve Hypoplasia, Septo-Optic Dysplasia and/or Infantile Nystagmus Syndrome.
- For traumatic retinal hemorrhages as seen in suspected shaken baby syndrome (See **Head Trauma (PEDHD-4.1)**)

References

1. Dumitrescu AV, Scruggs BA, Drack AV. Clinical Guidelines: Childhood Nystagmus Workup. American Academy of Ophthalmology. <https://www.aao.org/disease-review/clinical-guidelines-childhood-nystagmus-workup>. Published February 13, 2020.
2. Ganau M, Huet S, Syrmos N, Meloni M, Jayamohan J. Neuro-Ophthalmological Manifestations Of Septo-Optic Dysplasia: Current Perspectives Eye and Brain. 2019;Volume 11:37-47. doi:10.2147/eb.s186307.
3. Costello F, Scott JN. Imaging in Neuro-ophthalmology. CONTINUUM (MINNEAP MINN) 2019; 25(5, NEURO-OPHTHALMOLOGY): 1438–1490
4. Bhat R, Al-Samarraie M, Nada A, Leiva-Salinas C, Whitehead M, Mahdi E. Spotlight on the pediatric eye: a pictorial review of orbital anatomy and congenital orbital pathologies. Neuroradiol J. 2021 Feb;34(1):21-32. doi: 10.1177/1971400920949232.